Single-Cell Landscape of Colorectal Cancer Reveals Genomic Instability, Dysregulated Microenvironment, and Targetable Pathways
This single-cell RNA-seq analysis of human colon tissue provides a comprehensive view of colorectal cancer (CRC), highlighting distinct cellular populations and altered genomic states in the tumor microenvironment. Key findings include widespread aneuploidy in tumor-origin Intestinal Epithelial cells, significant shifts in immune and stromal cell compositions, and dysregulated cell-cell communication networks. We identified numerous tumor-specific surface markers and pathways involved in proliferation, inflammation, and immune evasion, offering insights into CRC pathogenesis and potential therapeutic strategies.
Contents
- Dataset overview
- Single-Cell UMAP Embedding Overview of Colon Tissue
- UMAP Visualization of Major Cell Type Scores, Ploidy, and Cell Type Annotations
- Celltype Subtype Marker Gene Expression Overview
- Tumor-Origin and Unassigned Cell CNV Analysis: Sample-Level Patterns and Significant Amplifications
- CNV-Aware UMAP Embedding of Colon Tissue Single-Cell RNA-seq Data
- Minor Cell Type Population Analysis in Colon Tissue
- T 세포 아형 인구 분포 분석 (정상 및 종양 조직 비교)
- T Cell and ILC Subset Population Differences in Colon Tumor Microenvironment
- Macrophage Subset Population Dynamics in Colon Cancer Microenvironment
- Macrophage Subset Population Shifts in Colon Tumor Microenvironment
- Ploidy Population Analysis of Intestinal Epithelial and Unassigned Cells in Colorectal Tissue
- Cell-Cell Interaction Patterns in the Colon Tumor Microenvironment
- Condition-Specific Cell-Cell Interaction Patterns in Colon Cancer
- Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Colorectal Tumor Microenvironment
- Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
- Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colon Tissue
- Condition-Specific Surfaceome Markers in Macrophages from Colon Tissue
- Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
- CD4 T cell Condition-Specific Surfaceome Markers in Colon Tissue
- Dysregulation of Cell Cycle Genes in Intestinal Epithelial Cells of Colon Tumors
- 장 상피세포(Intestinal Epithelial cell)의 유전자 온톨로지(GSA) 분석 결과
- Gene Set Enrichment Analysis Reveals Condition-Specific Pathway Alterations Across Colon Cell Types
- Discussion
- Query List
0. Dataset overview
데이터셋 요약
- 데이터 규모: 총 96,642개의 단일 세포와 27,779개의 유전자로 구성된 AnnData 객체입니다.
- 종 및 조직: 인간(human)의 대장(Colon) 조직 데이터입니다.
- 조건: 'tumor' (종양) 및 'adjacent_normal' (인접 정상)의 두 가지 주요 조건이 존재합니다.
주요 관측(obs) 컬럼:
- PatientTypeID, PID, Sex, Age, Ethnicity, Race: 환자 정보.
- SPECIMEN_TYPE, SOURCE_HOSPITAL, TISSUE_PROCESSING_TEAM, PROCESSING_TYPE, SINGLECELL_TYPE, batchID, sample, condition: 실험 및 샘플 정보.
- HistologicTypeSimple, MMRStatus, TumorStage, NodeStatusSimple, MetastasisStatus, TumorSize, Ploidy_dec: 임상 및 종양 특성 정보.
- celltype_major, celltype_minor, celltype_subset: 세포 유형 계층 구조 (예: Intestinal Epithelial cell, Myeloid cell 등).
- ploidy_dec: 이배체(Diploid) 또는 이수체(Aneuploid)로 구분되는 핵형 정보.
- cluster, cnv_cluster: 클러스터링 결과.
- 주요 변수(var) 컬럼: gene_ids, feature_types, genome, chr, cytogenetic_band 등 유전자 관련 정보.
사전 계산된 결과:
- uns['CCI']: 조건별(per condition) 세포-세포 상호작용 (CellPhoneDB) 결과.
- uns['CCI_sample']: 샘플별(per sample) 세포-세포 상호작용 (CellPhoneDB) 결과.
- uns['DEG']: 각 세포 유형(celltype_minor)에 대해 한 조건을 다른 조건과 비교한 차등 발현 유전자 (DEG) 결과.
- uns['GSEA']: 각 세포 유형(celltype_minor)에 대해 한 조건을 다른 조건과 비교한 유전자 세트 농축 분석 (GSEA) 결과.
- uns['GSA_up']: 각 세포 유형(celltype_minor)에 대해 한 조건을 다른 조건과 비교한 GO (GSA) 결과.
- obsm['X_cnv']: CNV (Copy Number Variation) 추정치.
1. Single-Cell UMAP Embedding Overview of Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a Uniform Manifold Approximation and Projection (UMAP) visualization of single-cell RNA-seq data from human colon tissue, comprising 96,642 cells and 27,779 genes. The UMAP plots are colored by several key metadata features: condition (tumor vs. adjacent_normal), sample, celltype_major, celltype_minor, ploidy_dec (aneuploidy status), and celltype_subset. This visualization aims to provide an overview of cellular heterogeneity, sample integration, and the distribution of biological states within the dataset.
Visual Summary
Condition
The UMAP colored by condition shows a clear separation between tumor (purple) and adjacent_normal (maroon) cells in several major clusters. The large cluster in the bottom-right quadrant and a smaller cluster on the far-right are predominantly composed of tumor cells. Other regions, particularly on the left and top-center, show a more mixed distribution or are dominated by adjacent_normal cells. This indicates distinct global transcriptional profiles associated with the tumor microenvironment compared to normal colon tissue.
Sample
The sample UMAP displays a broad distribution of cells from various samples (represented by many colors) across the entire embedding. This indicates that cells from different patients are largely well-mixed, suggesting effective integration of the dataset and minimal strong sample-specific batch effects that would otherwise lead to samples clustering independently of cell identity or condition.
Major Cell Type (celltype_major)
The Intestinal Epithelial cell (light yellow) population forms a prominent, large cluster, primarily localized in the bottom-right and central-right regions of the UMAP. This area largely overlaps with the tumor condition. T cell (cyan) and Myeloid cell (light green) populations form other substantial and distinct clusters, indicative of significant immune cell presence. Stromal cell (dark green) and Endothelial cell (orange) also form well-defined clusters. B cell (maroon) is present in smaller, distinct clusters. A relatively small fraction of cells remains unassigned (dark purple).
Minor Cell Type (celltype_minor)
At a higher resolution, Intestinal Epithelial cell (yellow) continues to define the clusters associated with the tumor. Macrophage (light yellow/green), T cell CD4+ (dark blue), and T cell CD8+ (purple) emerge as key immune cell populations, forming distinct and often large clusters. Fibroblast (orange) and Endothelial cell (red) populations are also clearly delineated. Other minor cell types like Plasma cell, DC, ILC, Mast cell, NK cell, and Smooth muscle cell form smaller but identifiable clusters.
Ploidy Status (ploidy_dec)
The ploidy_dec UMAP is particularly informative. Aneuploid cells (maroon) are strikingly concentrated within the large cluster in the bottom-right, which corresponds to the Intestinal Epithelial cell major type and predominantly to the tumor condition. This strong co-localization serves as a robust indicator of malignant epithelial cells. Diploid cells (yellow) are widely distributed across the rest of the UMAP, encompassing all non-malignant immune, stromal, and normal epithelial cell populations. A small number of cells are labeled as Unclear (purple).
Cell Type Subset (celltype_subset)
The most granular annotation, celltype_subset, reveals further heterogeneity within the major and minor cell types. Within the epithelial compartment, specific subtypes like Enterocyte, Crypt cell, Goblet cell, Paneth cell, Tuft cell, Microfold cell, Enteroendocrine cell, and Enterochromaffin cell are discernible. Immune cell clusters resolve into specialized populations such as T cell (Treg), T cell (Th17), T cell (Cytotoxic), different Macrophage subtypes (e.g., Mac_M1, Mac_M2a/b/c/d), and various B cell subsets (e.g., B cell (Memory), B cell (Follicular)). This level of detail provides fine-grained insights into the cellular composition of the colon tissue and its changes in disease.
Biological Interpretation
The UMAP analysis provides a comprehensive overview of the single-cell landscape of colon tissue in both tumor and adjacent normal conditions.
- Identification of Malignant Cells: The distinct clustering of Aneuploid cells, exclusively within the Intestinal Epithelial cell population that co-localizes with the tumor condition, strongly identifies the malignant epithelial cells forming the core of the colorectal tumor. This is a critical initial step for any downstream tumor-specific analysis.
- Tumor Microenvironment (TME) Complexity: The presence and distinct clustering of diverse immune (T cells, B cells, Myeloid cells, ILCs) and stromal (Fibroblasts, Endothelial cells, Smooth muscle cells) cell types highlight the complex cellular composition of the colon TME. The distribution of these cell types across tumor and adjacent normal regions indicates changes in cellular proportions and states driven by the disease.
- Cellular Heterogeneity: The hierarchical cell type annotations (major, minor, subset) effectively capture the considerable heterogeneity within both epithelial and non-epithelial compartments. For instance, the resolution of multiple macrophage and T cell subsets suggests a nuanced immune response and distinct functional states in different tissue environments. Similarly, the diverse epithelial cell subtypes reflect the intricate architecture of the colon lining.
- Dataset Quality and Integration: The general mixing of cells from different samples across the UMAP indicates successful integration of data from multiple patients, suggesting that patient-specific batch effects have been well-handled and do not obscure major biological distinctions.
Annotation Notes
The UMAP visualizations demonstrate high-quality cell type annotations that are consistent across different levels of granularity (major, minor, subset). The clear separation of cell populations and their biological relevance (e.g., aneuploidy indicating tumor cells) strongly support the reliability of the cell assignments. The relatively small fraction of "unassigned" cells across all annotation levels further indicates comprehensive coverage of the cellular landscape. The clear distinction between tumor and adjacent normal cells, together with the absence of significant sample-driven clustering, suggests that the dataset is well-structured for further in-depth biological investigations.
2. UMAP Visualization of Major Cell Type Scores, Ploidy, and Cell Type Annotations
[Analysis Visualization Results]...
Analysis Overview
This analysis presents UMAP visualizations that project cell type scores for various major cell types onto the single-cell RNA-seq embedding. These scores, derived from the HiCAT method, indicate the confidence of each cell belonging to a specific major cell type. For comparison and validation, the UMAP is also displayed with ploidy_dec (Aneuploid/Diploid status) and the final celltype_major annotations. This helps assess the quality of cell type identification and the overall structure of the single-cell dataset.
Visual Summary
The UMAP plots provide a comprehensive overview of cell populations and their characteristics within the dataset:
Major Cell Type Scores (HiCAT_major_score)
- T cell: High scores (yellow regions) are concentrated in a large, distinct cluster on the left side of the UMAP, indicating a prominent T cell population.
- B cell: A well-defined cluster with high B cell scores is visible towards the upper left region of the UMAP.
- Myeloid cell: Myeloid cells form a distinct cluster in the upper-middle section, separate from T and B cell populations.
- Mast cell: Mast cells appear as a smaller, more diffuse population, with higher scores in a specific, less dense region.
- Endothelial cell: High endothelial cell scores are concentrated in a smaller, distinct cluster on the far upper-right side.
- Stromal cell: Stromal cells also form a clear, separate cluster in the upper-right region, adjacent to endothelial cells.
- Enteric neuron: This population shows very low scores across most of the UMAP, with only a few sparse cells showing slightly elevated scores, suggesting it might be a rare or less distinct population, or potentially a misannotation if the score range is very low compared to other types. The maximum score is around 0.7, much lower than other cell types.
- Intestinal Epithelial cell: High scores for Intestinal Epithelial cells are predominantly found in a large cluster occupying the lower-middle and right-middle parts of the UMAP. This cluster is geographically distinct from immune and stromal cell populations.
Ploidy Status (ploidy_dec)
- The ploidy_dec plot shows a clear segregation. A significant cluster of Aneuploid cells (red) is visible, primarily mapping to the large cluster in the lower-middle/right-middle of the UMAP.
- The vast majority of cells in other regions (immune, stromal, endothelial) are labeled as Diploid (yellow).
- A small number of "Unclear" cells (purple) are scattered.
Major Cell Type Annotation (celltype_major)
- This plot presents the discrete, assigned major cell type labels. It shows distinct clusters for "T cell" (teal), "B cell" (maroon), "Myeloid" (light green), "Endo" (coral), "Stromal cell" (light yellow), and "Int.Epi" (orange).
- The "unassigned" cells (purple) are mostly found at cluster boundaries or in less dense regions, indicating cells that could not be confidently classified into a major type.
Biological Interpretation
- Robust Cell Type Segregation: The UMAP plots, particularly those showing major cell type scores, demonstrate excellent segregation of distinct cell populations. T cells, B cells, Myeloid cells, Intestinal Epithelial cells, Endothelial cells, and Stromal cells each occupy unique and well-defined regions in the embedding. This clear separation supports the high quality of the single-cell data processing and clustering.
- Concordance of Cell Type Scores and Annotations: There is a strong concordance between the continuous HiCAT major cell type scores and the discrete celltype_major annotations. For example, regions with high "HiCAT_major_score: T cell" precisely overlap with the cluster labeled "T cell" in the celltype_major plot. This consistency validates the accuracy of the cell type assignments.
- Identification of Tumor Cells via Ploidy: The ploidy_dec plot clearly identifies a large population of Aneuploid cells. Critically, this aneuploid population strongly overlaps with the region identified as "Intestinal Epithelial cell" by both the HiCAT score and the celltype_major annotation. Given the data context stating "Tumor origin celltype: Intestinal Epithelial cell" and "conditions: tumor, adjacent_normal," this strongly indicates that these aneuploid Intestinal Epithelial cells represent the malignant tumor cells. This is a common characteristic of many cancers, where genomic instability leads to widespread chromosomal abnormalities GeneCards: TP53.
- Normal/Stromal/Immune Cells are Diploid: Conversely, the vast majority of immune cells (T cells, B cells, Myeloid cells), stromal cells, and endothelial cells are identified as Diploid. This is expected for healthy, non-malignant cells and reinforces the distinction between the tumor compartment and the tumor microenvironment (TME) components.
- Rare Cell Types and Potential Ambiguity: The "Enteric neuron" scores are notably low across the UMAP, suggesting this cell type might be very rare, poorly captured, or the scoring model for it is less confident compared to other major types. The "unassigned" cells are likely those that exhibit mixed features or do not strongly express markers for any single major type, warranting further investigation if precise identification is required.
Annotation Notes
- The visual evidence strongly supports the quality of the celltype_major annotations. The distinct clustering on the UMAP for each major cell type, coupled with the high concordance between the HiCAT major scores and the assigned labels, indicates that the cell populations are well-resolved and accurately identified.
- The clear separation of aneuploid (tumor) Intestinal Epithelial cells from diploid normal and stromal/immune cells provides a robust framework for subsequent analyses comparing tumor-specific biology with the surrounding microenvironment. This distinction is crucial for understanding tumor progression and microenvironment interactions in colorectal cancer.
- The overall embedding structure is well-defined, allowing for clear differentiation of major cellular compartments present in the colon tissue samples.
3. Celltype Subtype Marker Gene Expression Overview
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a dot plot visualizing the expression of marker genes across various celltype_subset populations identified from single-cell RNA-seq data of human colon tissue. The purpose of this plot is to assess the specificity and average expression levels of key genes for each cell type subset, thereby validating the quality and biological consistency of the cell type annotations. The size of each dot corresponds to the fraction of cells within a given group that express the gene, while the color intensity reflects the mean expression level of that gene in the group. Importantly, the marker discovery focused on surfaceome-only genes, and genes common to three or more cell groups were excluded to emphasize specificity.
Visual Summary
The dot plot generally shows distinct patterns of marker gene expression, with many celltype_subset populations exhibiting strong and specific expression of a limited set of genes (indicated by large, dark red dots primarily confined to a single row/cell type). Red boxes highlight groups of genes that are highly specific to certain cell type subsets, supporting their unique identities.
Notable observations include:
- Lymphoid Cells: B cell subtypes (Breg, MZ, Memory) demonstrate clear expression of B cell-associated transcription factors (e.g., POU2AF1). T cell subsets (Cytotoxic, Th17, Treg) show specific markers like GZMB and CD8A for Cytotoxic T cells, RORA for Th17 cells, and CTLA4 for Treg cells. Plasma cells are characterized by strong expression of canonical markers such as MZB1, SDC1 (CD138), and TNFRSF17 (BCMA). NK cells express characteristic markers like KLRD1 (CD94) and FCGR3A (CD16). Dendritic cell subtypes (Classical, Plasmacytoid) are well-differentiated by specific markers like CD83/CD86 for Classical DCs and LILRA4/CLEC4C for Plasmacytoid DCs.
- Myeloid Cells: Macrophage subtypes (M1, M2A, M2B, M2C, M2D) show a general macrophage marker CD68, with CD163 notably prominent in M2A macrophages. Mast cells are distinctly marked by KIT (CD117), TPSAB1, and SRGN.
- Epithelial Cells: Intestinal epithelial subsets, such as Crypt cells (ASCL2, AXIN2), Goblet cells (MUC2, TFF3), and Paneth cells (LYZ), exhibit highly specific and well-established lineage markers. Tuft cells also show expression of SOX9.
- Stromal/Endothelial Cells: Fibroblasts express extracellular matrix and contractile protein genes (e.g., COL1A1, DCN, ACTA2, TAGLN). Smooth muscle cells are strongly identified by contractile genes like ACTA2, MYL9, and TAGLN. Lymphatic Endothelial cells are marked by PROX1 and LYVE1.
Biological Interpretation
The observed marker gene expression largely aligns with the known biological functions and identities of the annotated cell type subsets, providing strong evidence for the validity of most cell annotations.
- Immune Cell Lineages: The clear delineation of B, T, NK, Plasma, Dendritic, Macrophage, and Mast cell populations by established surface markers and lineage-specific transcription factors (e.g., POU2F family for B cells, CD8A/GZMB for cytotoxic T cells, LILRA4/CLEC4C for pDCs, KIT for Mast cells, SDC1/MZB1 for Plasma cells) indicates a robust and accurate annotation of the immune landscape in the colon tissue. The distinction between macrophage polarization states (e.g., M1 vs. M2A with CD163) also reflects known macrophage plasticity GeneCards: CD163.
- Intestinal Epithelial Diversity: The specific markers for Crypt cells (stem/progenitor-like with ASCL2, AXIN2), Goblet cells (mucin-producing with MUC2, TFF3), and Paneth cells (antimicrobial peptide-secreting with LYZ) confirm the successful resolution of specialized epithelial cell types, crucial for intestinal homeostasis and function GeneCards: ASCL2, GeneCards: MUC2, GeneCards: LYZ.
- Stromal Compartment: The identification of Fibroblasts and Smooth Muscle Cells via their characteristic expression of collagen genes, extracellular matrix components, and contractile proteins (e.g., ACTA2, TAGLN) highlights the structural and functional diversity of the stromal microenvironment. Lymphatic Endothelial cells are clearly identifiable by PROX1 and LYVE1, markers critical for lymphatic vessel identity and function GeneCards: PROX1.
Annotation Notes
While most cell type subsets are well-supported by their marker gene expression, some observations warrant further attention for refining the annotations:
- Endothelial Cell and Enterocyte Marker Overlap: A notable concern is the significant overlap in marker gene expression between the "Endothelial cell" and "Enterocyte" populations. Genes such as CDX1, CDX2, VIL1, MUC13, and KRT20, which are canonical intestinal epithelial markers GeneCards: CDX2, are strongly expressed in both cell types. This is biologically unexpected and suggests potential issues:
- Misannotation: There might be mislabeled cells within the "Endothelial cell" cluster that are genuinely epithelial, or vice-versa.
- Sample Contamination: The endothelial cell cluster might be contaminated with epithelial cells during sample processing or data integration.
- Marker Selection: While the surfaceome_only and rem_mkrs_common_in_N_groups_or_more parameters aim for specificity, this particular overlap might reflect biological complexity not fully resolved by current annotation or marker lists. Further investigation using additional context-specific markers or re-clustering of these populations might be necessary.
- ILC Subtypes: Several ILC subtypes (ILCreg, ILC2, ILC3 (NCR+), ILC3 (NCR-)) do not display a robust set of highly specific markers in this plot. This could indicate that the selected markers are not sufficiently discriminative for these rarer or phenotypically more subtle populations, or that their transcriptional profiles are more fluid, making sharp distinctions challenging.
- Microfold Cell and ILC1/LTI Shared Marker: The gene 'LTI' is shown as a marker for both "Microfold cell" and "ILC1" and the cell type "LTI" (which likely refers to Lymphoid Tissue Inducer cells). While LTi cells are a type of ILC, and some shared features might exist due to developmental origins or microenvironmental interactions, the strong shared marker with Microfold cells (a specialized epithelial cell) needs careful re-evaluation to confirm unique cell identities.
4. Tumor-Origin and Unassigned Cell CNV Analysis: Sample-Level Patterns and Significant Amplifications
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates copy number variations (CNVs) in Intestinal Epithelial cells (identified as the tumor-origin cell type) and unassigned cells, grouped by individual samples. The primary goal is to visualize genomic gains (amplifications) and losses (deletions) across chromosomes in these cell populations and to identify significantly amplified regions, particularly focusing on those frequently observed across samples. The ploidy_dec annotation, indicating whether a cell population is predominantly Aneuploid or Diploid, helps in distinguishing tumor-like from potentially non-tumor or less malignant populations within samples.
Visual Summary
log2(CNR) Heatmap (Top Figure)
The heatmap displays the log2 ratio of copy number estimates (log2(CNR)) for genomic spots across all chromosomes (chr1-chr22) for selected cell populations (Intestinal Epithelial cells and unassigned cells) grouped by sample.
- Genomic Alterations: Red regions indicate genomic amplifications (log2(CNR) > 0), while blue regions indicate deletions (log2(CNR) < 0). Darker shades represent stronger alterations.
- Sample Heterogeneity: There is clear heterogeneity in CNV patterns across different samples. Some samples, notably those prefixed with "Diploid" (e.g., Diploid C106, Diploid C108), show largely uniform, near-zero log2(CNR) values (black/dark brown), indicating a predominantly diploid genomic state with minimal CNVs. These samples likely contain mostly healthy or less transformed cells, or represent samples where the tumor cells are diploid.
- Aneuploid Samples: Samples without the "Diploid" prefix (e.g., C103, C104, C109, C112, C125) exhibit widespread and significant CNVs, characterized by prominent red and blue regions. This pattern is highly indicative of aneuploidy, a hallmark of cancer, and suggests these samples contain a substantial proportion of tumor cells.
- Recurrent CNV Hotspots: Within the aneuploid samples, several regions show recurrent amplifications. For example, substantial amplifications are visible on chromosomes 7, 8, 13, and 20, among others, appearing as prominent red vertical streaks across multiple samples. Deletions are also observed, though less uniformly across the set of aneuploid samples in this view.
Significant Amplification Summary (Bottom Figure)
This heatmap and associated bar chart summarize the frequency of significant amplifications within specific cytogenetic bands across the analyzed samples.
- Frequent Amplifications: The bar chart on the right highlights the overall frequency of amplification for each cytogenetic band across all samples. High-frequency amplifications are observed for:
- 20q13.2:20q13.3 (frequency ~0.91): This region shows the highest amplification frequency.
- 7p12.3:7q21.12 (EGFR) (frequency ~0.68): Amplification of this region, containing the *EGFR* gene, is notable.
- 8p21.1:8q24.3 (EIF3E, DDHD2, TPDS2, GSDMD, LSM1, INTS8, COP55) (frequency ~0.68): This broad region also shows high amplification.
- 17q12:17q21.2 (ERBB2) (frequency ~0.32): Amplification of *ERBB2* is also present, though less frequent than *EGFR* or 20q.
- Other regions like 1q21.3:1q23.2, 1q41:1q44, 6p22.1:6p23.2, and 12q24.23:12q24.33 also show significant amplification frequencies (0.50, 0.41, 0.59, 0.45, 0.27 respectively).
- Sample-Specific Patterns: The heatmap portion shows that while some amplifications are widespread (e.g., 20q13.2:20q13.3 across most aneuploid samples), others are more specific to certain samples or subsets of samples. For instance, samples C103, C104, C109, C112, C125, C130, C138, C140, C145, C149, C150, C153, C158, C160, C162, C163, C166, C171 predominantly contribute to the observed amplifications, aligning with the visually aneuploid samples in the top heatmap. The "Diploid" samples show values of 0.0 or very low frequencies for most amplified regions, confirming their largely normal genomic status.
Biological Interpretation
The analysis of tumor-origin Intestinal Epithelial cells and unassigned cells reveals distinct genomic profiles corresponding to their inferred ploidy status. Samples designated as "Diploid" largely maintain a normal copy number state, suggesting these may represent normal epithelial cells, adjacent normal tissue, or potentially well-differentiated tumors that haven't acquired widespread aneuploidy. In contrast, samples showing extensive amplifications and deletions are characteristic of transformed, aneuploid tumor cells.
The identification of recurrent genomic amplifications is particularly insightful:
- EGFR Amplification (7p12.3:7q21.12): The epidermal growth factor receptor (*EGFR*) gene is a well-known proto-oncogene. Its amplification is a common event in various cancers, including colorectal cancer (CRC), and is associated with increased cell proliferation, survival, and resistance to apoptosis. High *EGFR* expression due to amplification can drive tumor growth and is often targeted by specific therapies [PubMed search: EGFR amplification colorectal cancer].
- ERBB2 Amplification (17q12:17q21.2): *ERBB2* (also known as *HER2*) is another receptor tyrosine kinase proto-oncogene. While most famously amplified in breast and gastric cancers, *ERBB2* amplification and overexpression also occur in a subset of CRC, often correlating with more aggressive disease and providing a rationale for *HER2*-targeted therapies [PubMed search: ERBB2 amplification colorectal cancer].
- 20q13 Amplification: Amplification of the 20q arm, particularly 20q13, is a very common event in various solid tumors, including CRC. This region harbors several genes involved in cell cycle regulation, apoptosis inhibition, and cell migration, such as *AURKA* (Aurora Kinase A) and *ZNF217*, contributing to oncogenesis when amplified [GeneCards: AURKA, GeneCards: ZNF217]. Its high frequency in these samples underscores its importance in colorectal tumor development.
- 8q Amplification: The 8q arm, including 8p21.1:8q24.3, is frequently amplified in CRC. This region contains numerous genes, including *MYC*, a powerful oncogene, and others like *EIF3E*, *DDHD2*, *TPDS2*, *GSDMD*, *LSM1*, *INTS8*, *COP55* which may collectively contribute to tumorigenesis when amplified. *MYC* amplification, in particular, is a strong driver of proliferation and metabolism in cancer cells [GeneCards: MYC].
- The "unassigned" cells, when grouped by sample, appear to largely follow the CNV patterns of the dominant cell type in that sample, implying that some "unassigned" cells in aneuploid samples might also be tumor cells or tumor-associated stromal/immune cells that have undergone genomic changes, or simply tumor cells that couldn't be definitively assigned to a specific epithelial subtype.
Clinical or Translational Implications
The recurrent amplifications identified in tumor-origin Intestinal Epithelial cells have significant clinical and translational implications for colorectal cancer:
- Biomarker for Prognosis and Therapy: Amplifications of *EGFR* and *ERBB2* are established biomarkers. Detection of *EGFR* amplification can predict response to anti-EGFR therapies (e.g., cetuximab, panitumumab) in metastatic CRC, particularly in *RAS* wild-type patients [PubMed search: anti-EGFR therapy colorectal cancer]. Similarly, *ERBB2* amplification identifies patients who might benefit from *HER2*-targeted therapies (e.g., trastuzumab, pertuzumab), which are increasingly being explored in CRC [PubMed search: HER2 targeted therapy colorectal cancer].
- Disease Subtyping: The clear distinction between diploid and aneuploid samples based on their CNV profiles reinforces the genomic heterogeneity of CRC. This could aid in classifying tumors into distinct subtypes with different prognoses and therapeutic vulnerabilities.
- Novel Therapeutic Targets: While *EGFR* and *ERBB2* are well-known, other frequently amplified regions like 20q13 and 8q (including *MYC*) highlight potential areas for identifying novel therapeutic targets or understanding resistance mechanisms. Further investigation into the specific genes within these broad amplification regions could reveal additional actionable targets.
- Understanding Tumor Evolution: The widespread aneuploidy observed in many samples underscores the genomic instability characteristic of advanced colorectal cancer, contributing to tumor evolution and drug resistance. Monitoring these CNV patterns could potentially track disease progression or response to treatment.
5. CNV-Aware UMAP Embedding of Colon Tissue Single-Cell RNA-seq Data
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the single-cell RNA-seq data on a UMAP embedding, which was generated using CNV estimates (obsm['X_cnv']), allowing for the assessment of chromosomal instability patterns. The UMAP plots are colored by various metadata: major cell types, minor cell types, ploidy inference (ploidy_dec), sample condition, and individual sample IDs. This helps to understand how different cellular identities, ploidy states, and experimental conditions are represented and spatially organized in a CNV-informed transcriptional landscape.
Visual Summary
The UMAP plots reveal distinct patterns and relationships between cell states, ploidy, and conditions:
- Celltype Major: The UMAP displays well-segregated clusters corresponding to major cell types. "Intestinal Epithelial cell" forms a large, somewhat diffuse population, while "T cell" and "B cell" form distinct, tightly clustered groups. "Myeloid cell", "Endothelial cell", and "Stromal cell" also show clear clustering. This indicates that major cell type identities are robustly captured in this CNV-aware embedding.
- Celltype Minor: At the minor cell type resolution, the patterns largely refine the major clusters. For instance, different subtypes of "Intestinal Epithelial cell" (e.g., "Enterocyte", "Crypt cell") further delineate the main epithelial cluster. Similarly, "T cell CD4+" and "T cell CD8+" occupy distinct regions within the broader T cell cluster. This confirms the hierarchical nature of cell identity in the embedding.
- Ploidy Status (ploidy_dec): A striking feature is the clear separation of cells based on their ploidy. A distinct and relatively compact cluster of "Aneuploid" cells (dark red) is evident, primarily located on the right side of the UMAP. The vast majority of other cells are labeled "Diploid" (light yellow), forming a large, more distributed region across the left and central parts of the UMAP. This strong segregation highlights the effectiveness of the CNV embedding in distinguishing cells with altered chromosomal content.
- Condition: The "condition" plot shows a clear association between the "tumor" condition (purple-blue) and the "Aneuploid" cluster observed in the ploidy_dec map. Tumor cells predominantly occupy this aneuploid region. Conversely, "adjacent_normal" cells (dark red) are primarily found within the larger "Diploid" region. There is some mixing, especially in areas likely representing immune and stromal cells that are present in both tumor and normal tissues.
- Sample: The "sample" plot displays a mosaic of different sample IDs across the UMAP. In the large "Diploid" region, cells from various samples appear relatively well-mixed, suggesting minimal technical batch effects across samples for these populations. However, within the "Aneuploid" / "tumor"-enriched cluster, there are visible sub-clusters where specific samples appear to dominate, indicating patient-specific chromosomal alterations or clonal expansions within the tumor.
Biological Interpretation
The CNV-aware UMAP embedding provides critical biological insights into the cellular composition and genomic integrity within the colon tissue dataset:
- Identification of Malignant Cells: The most significant observation is the clear segregation of "Aneuploid" cells into a distinct cluster. This cluster strongly overlaps with cells labeled "tumor" and corresponds to a significant portion of the "Intestinal Epithelial cell" population. This is highly consistent with the known Tumor origin celltype: Intestinal Epithelial cell and the understanding that colorectal cancer often arises from epithelial cells undergoing extensive chromosomal instability, leading to aneuploidy.
- Distinguishing Tumor from Normal Epithelium: The ability of the CNV-informed UMAP to sharply separate aneuploid, tumor-associated epithelial cells from diploid, likely normal cells is a powerful validation of the analysis. This suggests that CNV estimates from scRNA-seq can effectively differentiate malignant epithelial cells from their non-malignant counterparts, even within complex tissue microenvironments.
- Tumor Microenvironment Composition: Non-epithelial cell types, such as "T cell", "B cell", "Myeloid cell", and "Stromal cell", are predominantly diploid and are distributed across both "tumor" and "adjacent_normal" regions of the UMAP. This reflects their role as components of the tumor microenvironment (infiltrating immune cells, cancer-associated fibroblasts) and as resident cells in normal tissue. Their diploid status further confirms that the detected aneuploidy is specific to the malignant epithelial lineage.
- Patient Heterogeneity: While non-malignant cells show good sample mixing, the presence of sample-specific sub-clusters within the aneuploid tumor region suggests inter-patient heterogeneity in tumor CNV patterns, which is a well-documented aspect of cancer genomics PubMed search: tumor heterogeneity clonal evolution cancer.
Annotation Notes
The provided UMAP visualization based on CNV estimates demonstrates excellent annotation quality and structural clarity. The distinct separation of cell clusters by major and minor cell types, combined with the clear demarcation of aneuploid (malignant) versus diploid cells, validates the cell type annotations and the reliability of the ploidy inference. The correlation between aneuploidy, tumor condition, and the expected tumor origin cell type (Intestinal Epithelial cell) further reinforces the biological accuracy of the dataset's annotations and the robustness of the CNV embedding method. The observation of good sample mixing in non-malignant populations, while retaining patient-specific patterns in malignant cells, suggests appropriate handling of batch effects during data integration.
6. Minor Cell Type Population Analysis in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents the cellular composition at the minor cell type level across individual samples, comparing adjacent normal colon tissue with tumor tissue. The stacked bar plots illustrate the proportional abundance of each identified cell type within each sample, providing insights into potential shifts in the cellular microenvironment associated with colon cancer.
Visual Summary
The visualization consists of two panels, one for "adjacent_normal" and one for "tumor," each displaying stacked bar plots representing the cell type composition of individual samples. Each bar sums to 100%, with different colors representing distinct minor cell types as indicated by the legend.
Key observations include:
- Dominant Cell Types: Intestinal Epithelial cells (light orange) are a substantial component in both adjacent normal and tumor samples. T cells (CD4+ in teal and CD8+ in blue) are also consistently present across most samples.
Tumor-associated Shifts:
- Intestinal Epithelial cell enrichment: Many tumor samples show a visually higher proportion of Intestinal Epithelial cells compared to adjacent normal samples. This is particularly noticeable in samples such as C15_9, C15_13, C15_24, C15_28, C15_34, C15_41, C15_46, and C15_49 within the tumor group, where this population often accounts for 40-70% or more of the total cells. This is expected given that Intestinal Epithelial cells are the tumor origin cell type.
- Immune Cell Heterogeneity: The proportions of immune cells, including T cells (CD4+, CD8+), B cells (dark red), and Macrophages (yellow), show variability across samples. While present in both conditions, some tumor samples appear to have relatively lower overall proportions of T cells compared to some adjacent normal samples, potentially indicating immune evasion or displacement by tumor cells. Conversely, specific tumor samples show notable proportions of B cells (e.g., C15_12, C15_28, C15_40) or Macrophages, which could represent specific immune infiltrates within the tumor microenvironment.
- Stromal Components: Fibroblasts (orange-red) are consistently observed in both conditions, and their proportions also vary across samples. Endothelial cells, Dendritic cells, and other minor cell types are present in smaller, yet consistent, proportions.
- Sample-to-Sample Variability: Significant heterogeneity in cell type proportions is observed between individual samples within both the adjacent normal and tumor groups, highlighting the patient-specific nature of the tissue microenvironment.
- Unassigned Cells: A small proportion of cells remain 'unassigned' (dark blue) in many samples, generally not forming a major component.
Biological Interpretation
The observed shifts in cell type proportions between adjacent normal and tumor colon tissue provide critical insights into the tumor microenvironment (TME) in human colorectal cancer.
- Tumor Epithelial Cell Expansion: The increased proportion of Intestinal Epithelial cells in tumor samples is a fundamental biological finding, directly reflecting the proliferation and expansion of neoplastic cells that constitute the tumor mass [NCBI]. This observation is consistent with the disease state where tumor epithelial cells outgrow and often displace normal tissue components.
Remodeling of the Immune Microenvironment:
- The presence of T cells (CD4+ and CD8+) in both conditions is expected, as these are key components of local immune surveillance. However, the apparent decrease in the *relative proportion* of T cells in some tumor samples may suggest immune cell exclusion, exhaustion, or dilution by the expanding tumor cells. The specific balance of T cell subsets (e.g., cytotoxic CD8+ T cells vs. regulatory T cells) within the TME is crucial for anti-tumor immunity [NCBI].
- Macrophages are prominent, and their presence in tumors often points to tumor-associated macrophages (TAMs). TAMs can exert diverse functions, including promoting tumor growth, angiogenesis, and immunosuppression, depending on their polarization (e.g., M1 vs. M2 phenotypes) [NCBI].
- The variable presence of B cells and Plasma cells could indicate the formation of tertiary lymphoid structures (TLS) within the tumor, which can be associated with both anti-tumor and pro-tumor immune responses depending on their maturation and cellular content [NCBI].
- Stromal Cell Dynamics: Fibroblasts are key components of the tumor stroma, often differentiating into cancer-associated fibroblasts (CAFs). CAFs play crucial roles in ECM remodeling, promoting tumor growth, invasion, and immunosuppression, contributing to the desmoplastic reaction often seen in colorectal cancer [NCBI]. Their consistent presence in both conditions, with potential increases in the tumor, highlights their involvement in the TME.
Clinical or Translational Implications
Understanding the cellular composition of the tumor microenvironment has significant clinical and translational implications:
- Biomarker Identification: The relative proportions of different immune and stromal cell types can serve as prognostic biomarkers, predicting disease progression or response to therapy. For example, higher infiltration of specific T cell subsets or certain types of macrophages is associated with better or worse outcomes in various cancers.
- Therapeutic Target Identification: Shifts in cell populations highlight potential therapeutic targets. For instance, if immunosuppressive cell types (e.g., certain macrophage subsets, regulatory T cells) are enriched in tumors, therapies aimed at depleting these cells or reprogramming their function could be explored. The presence of CAFs also indicates potential targets for stromal-targeted therapies.
- Immunotherapy Response Prediction: The immune cell landscape, particularly the ratio and localization of cytotoxic T cells versus immunosuppressive cells, is a critical determinant of response to immunotherapies like checkpoint inhibitors. These population plots can inform strategies for patient stratification for such treatments.
- Heterogeneity and Personalized Medicine: The observed sample-to-sample variability underscores the need for personalized approaches in cancer treatment. Cellular composition can vary significantly between patients, suggesting that a "one-size-fits-all" approach may not be optimal.
7. T 세포 아형 인구 분포 분석 (정상 및 종양 조직 비교)
[Analysis Visualization Results]...
Analysis Overview
이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 사용하여 대장 조직에서 T 세포 주요 세포 유형 내의 다양한 T 세포 및 선천 림프구 세포(ILC) 아형의 상대적 인구 분포를 시각화한 것입니다. 각 샘플에 대해 인접 정상(adjacent_normal) 조직과 종양(tumor) 조직을 비교하여 세포 아형 구성의 변화를 탐색합니다. 이는 대장암 미세 환경에서 면역 세포 구성 변화를 이해하는 데 중요한 정보를 제공합니다.
Visual Summary
제공된 막대 그래프는 T 세포 주요 세포 유형 내 다양한 세포 아형의 상대적 비율을 보여줍니다. 각 막대는 개별 샘플을 나타내며, adjacent_normal 및 tumor 조건으로 분류되어 있습니다.
- 주요 구성 요소: 두 조건 모두에서 T cell (Cytotoxic), T cell (Naive), T cell (Treg)이 T 세포 구획의 가장 큰 부분을 일관되게 차지하고 있습니다. 특히 T cell (Treg)은 두 조건 모두에서 상당한 비율로 존재하며, 일부 종양 샘플에서 인접 정상 샘플보다 상대적으로 더 높은 비율을 보이는 경향이 있습니다.
- 보조 구성 요소: 다른 헬퍼 T 세포 아형(예: T cell (Th1), T cell (Th17), T cell (Th2), T cell (Th22), T cell (Th9), T cell (Tfh))은 더 작고 가변적인 비율로 존재합니다. ILC(ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI) 및 NK cell은 전체 T 세포 구획에서 상대적으로 소수이지만 일관되게 관찰됩니다.
- 조건별 차이: adjacent_normal 및 tumor 조건 간에 T 세포 아형의 구성에서 샘플별 편차가 존재하지만, 전반적으로 T cell (Treg)의 상대적 비율이 종양 조직에서 다소 증가하는 경향이 관찰됩니다. unassigned된 T 세포 집단도 두 조건에서 존재하며 샘플마다 그 비율이 다릅니다.
Biological Interpretation
이러한 시각적 분석 결과는 대장암 미세 환경에서 면역 억제성 T 세포의 잠재적 증강을 시사합니다.
- Treg 세포의 역할: T cell (Treg)은 면역 반응을 억제하여 자가면역을 방지하는 중요한 역할을 합니다. 그러나 암 미세 환경에서는 Treg 세포가 면역 관문 억제제(immune checkpoint inhibitor)와 같은 항암 치료에 대한 반응을 저해하고 암세포의 면역 회피를 촉진할 수 있습니다. 일부 종양 샘플에서 Treg 세포의 상대적 증가 경향은 대장암에서 흔히 관찰되는 현상으로, 종양의 면역 억제적 특성을 강화하는 데 기여할 수 있습니다. PubMed: 32669460
- 세포독성 T 세포의 지속적인 존재: T cell (Cytotoxic)은 암세포를 직접적으로 제거하는 주요 면역 세포입니다. 종양 조직에서도 이들의 상당한 비율이 유지된다는 것은 활발한 항종양 면역 반응이 존재함을 시사하지만, Treg 세포의 존재는 이러한 반응의 효과를 감소시킬 수 있습니다.
- 다양한 헬퍼 T 세포 및 ILC: Th17, Th1 등의 헬퍼 T 세포 아형과 ILCs의 존재는 대장 조직의 복잡한 면역 환경을 반영합니다. Th1 세포는 일반적으로 항종양 면역에 기여하는 반면, Th17 세포와 ILCs는 암의 맥락에 따라 종양 촉진 또는 억제 역할을 할 수 있습니다. PubMed: 36768784 PubMed: 32265439
Clinical or Translational Implications
이러한 T 세포 아형 분포 패턴은 대장암의 병태생리학적 이해를 심화하고 새로운 치료 전략을 개발하는 데 중요한 함의를 가집니다.
- 면역 치료 반응 예측: 종양 미세 환경 내 Treg 세포 대 세포독성 T 세포의 비율은 면역 관문 억제제와 같은 면역 요법에 대한 환자의 반응성을 예측하는 바이오마커로 활용될 수 있습니다.
- 치료 표적 개발: Treg 세포의 기능을 억제하거나 세포독성 T 세포의 활성을 증강시키는 전략은 대장암 치료에 새로운 접근법을 제공할 수 있습니다. 예를 들어, Treg 세포를 선택적으로 고갈시키거나 그 억제 기능을 무력화하는 약물은 항종양 면역 반응을 강화할 수 있습니다.
- 질병 진행 이해: T 세포 아형의 변화는 종양의 성장, 전이 및 치료 저항성과 연관될 수 있으며, 이는 질병 진행의 메커니즘을 이해하는 데 기여합니다.
8. T Cell and ILC Subset Population Differences in Colon Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportional representation of various T cell and Innate Lymphoid Cell (ILC) subsets, as identified by 'celltype_subset', between colon tumor tissue and adjacent normal tissue. The boxplots illustrate the distribution of celltype proportions for each subset across these two conditions, with statistical significance determined using a specified test configuration (p-value cutoff of 0.1 and log2 fold change cutoff of 0.1).
Visual Summary
The boxplots reveal several significant and near-significant differences in the proportions of T cell and ILC subsets between tumor and adjacent normal tissues:
- Treg (Regulatory T cells): There is a statistically significant increase in the proportion of Treg cells in the tumor microenvironment compared to adjacent normal tissue (p ≤ 0.01). The median proportion of Tregs is higher in tumors.
- Th17 (T helper 17 cells): The proportion of Th17 cells tends to be higher in tumor tissue compared to adjacent normal, though this difference shows a trend towards significance (p = 0.06), falling just outside the common 0.05 cutoff but within the specified 0.1 cutoff.
- ILC2 (Group 2 Innate Lymphoid Cells): The proportion of ILC2s is significantly lower in tumor tissue compared to adjacent normal tissue (p = 0.05). In tumor samples, many samples show very low or zero ILC2 proportions.
- T_Naive (Naive T cells): Naive T cells show a trend towards lower proportions in tumor tissue compared to adjacent normal (p = 0.07). The median proportion is slightly lower in tumor, with more variability in the adjacent normal samples.
- ILCreg (Regulatory Innate Lymphoid Cells): There is a trend towards a higher proportion of ILCreg cells in tumor tissue compared to adjacent normal (p = 0.07).
Biological Interpretation
These observed shifts in T cell and ILC subsets provide insights into the immune landscape of colon cancer:
- Increased Tregs in Tumors: The significant enrichment of Regulatory T cells (Tregs) in the tumor microenvironment is a well-established phenomenon in many cancers, including colorectal cancer. Tregs are crucial for maintaining immune tolerance and are potent immunosuppressors, primarily by inhibiting the activity of effector T cells (like CD8+ cytotoxic T cells and Th1 cells). Their accumulation in tumors often correlates with a poor prognosis as they can dampen anti-tumor immune responses, allowing cancer cells to evade immune surveillance and proliferate. PubMed search: Regulatory T cells colorectal cancer prognosis
- Elevated Th17 in Tumors (Trend): Th17 cells have a dual role in cancer, sometimes promoting anti-tumor immunity and sometimes supporting tumor growth depending on the specific context and their plasticity. In colon cancer, Th17 cells can contribute to chronic inflammation that fuels tumor development or, under certain conditions, can participate in anti-tumor responses. The observed trend towards increased Th17 cells in tumors suggests their active involvement in the tumor-associated inflammatory processes in this cohort. PubMed search: Th17 cells colorectal cancer
- Decreased ILC2s in Tumors: Group 2 Innate Lymphoid Cells (ILC2s) are typically associated with type 2 immune responses, tissue repair, and anti-helminth immunity. Their reduction in tumor tissue might indicate a suppression or displacement of these cells in the tumor microenvironment, possibly shifting the immune response away from a type 2 profile. The role of ILC2s in colorectal cancer is complex; while some studies suggest they can promote anti-tumor immunity, others indicate they might support tumor growth through pro-tumorigenic cytokines. A decrease might suggest a loss of a beneficial immune component or a shift to a less type 2-polarized environment. PubMed search: ILC2 colorectal cancer
- Reduced Naive T cells in Tumors (Trend): A lower proportion of naive T cells in tumor tissue compared to adjacent normal is expected. Naive T cells primarily reside in lymphoid organs and circulate in the blood, awaiting activation. Their reduced presence in tumors might reflect their differentiation into effector or memory cells upon antigen encounter within the tumor microenvironment or nearby lymphoid structures, or simply less infiltration of naive cells into the active tumor site.
- Elevated ILCreg in Tumors (Trend): The trend for increased ILCreg (regulatory innate lymphoid cells) in tumors, similar to Tregs, hints at another layer of immune regulation and suppression within the tumor microenvironment. While less extensively studied than Tregs, ILCregs could contribute to the overall immunosuppressive milieu, potentially impacting the efficacy of anti-tumor immune responses.
Clinical or Translational Implications
The findings underscore the significant immune dysregulation within the colon tumor microenvironment:
- Immunosuppressive Landscape: The prominent increase in Tregs and a trend for increased ILCregs suggest a highly immunosuppressive environment in colon tumors. This has critical implications for immunotherapy, as these regulatory cells can counteract the effects of checkpoint inhibitors or other immune-boosting therapies.
- Prognostic Marker: High infiltration of Tregs is often associated with poorer clinical outcomes in colorectal cancer. Targeting Treg function or depletion strategies could be considered to enhance anti-tumor immunity. PubMed search: Treg depletion cancer therapy
- Therapeutic Opportunities: Understanding the balance between various T cell and ILC subsets, particularly the Th17/Treg axis and the role of ILC2s, could inform novel therapeutic strategies. For instance, interventions that re-balance the Th17/Treg ratio towards an anti-tumorigenic profile, or that prevent the reduction of potentially beneficial ILC2s, might improve patient outcomes.
- Biomarker Potential: The proportions of these cell subsets could serve as biomarkers for patient stratification, predicting response to immunotherapy, or monitoring disease progression.
9. Macrophage Subset Population Dynamics in Colon Cancer Microenvironment
[Analysis Visualization Results]...
Analysis Overview
이 분석은 단일 세포 RNA 시퀀싱 데이터를 활용하여 대장 조직 내 대식세포(Macrophage)의 하위 유형(M1, M2A, M2B, M2C, M2D) 분포를 인접 정상 조직(adjacent_normal)과 종양 조직(tumor) 간에 비교한 결과입니다. 각 막대 그래프는 개별 샘플(patient ID)에서 대식세포가 차지하는 비율을 100%로 보았을 때, 각 하위 유형이 구성하는 상대적 비율을 보여줍니다. 이는 대장암 발생 및 진행 과정에서 대식세포의 면역 기능 변화를 이해하는 데 중요한 통찰력을 제공합니다.
Visual Summary
- M1 대식세포의 우세: 인접 정상 조직과 종양 조직 모두에서 M1 대식세포(짙은 자주색)가 전체 대식세포 중 가장 큰 비중을 차지하고 있습니다.
- 종양 조직에서의 M2형 대식세포 증가 경향: 종양 조직에서는 인접 정상 조직에 비해 M2A(주황색) 및 M2B(옅은 노란색) 대식세포의 비율이 상대적으로 증가하는 경향이 관찰됩니다. 특히 M2A 대식세포의 경우 일부 종양 샘플에서 그 비율이 더욱 두드러지게 나타납니다.
- M2C 및 M2D 대식세포: M2C(옅은 연두색) 및 M2D(청록색) 대식세포는 두 조건 모두에서 상대적으로 낮은 비율을 차지하며, 조건 간에 뚜렷한 증가 또는 감소 추세는 보이지 않습니다.
- 환자 간 이질성: 각 샘플(환자)마다 대식세포 하위 유형의 구성 비율에 상당한 이질성이 존재합니다. 이는 대장암 환자 개개인의 면역 반응 특성이 다를 수 있음을 시사합니다.
Biological Interpretation
대식세포는 종양 미세환경(TME)에서 중요한 역할을 하는 면역 세포로, 그들의 기능은 M1(고전적 활성화)과 M2(대안적 활성화)라는 두 가지 주요 극성으로 나눌 수 있습니다.
- M1 대식세포는 일반적으로 항종양성(pro-inflammatory, anti-tumor) 반응을 유도합니다. 이들은 종양 세포를 직접 공격하고, T 세포 반응을 촉진하며, IFN-$\gamma$와 같은 염증성 사이토카인을 분비합니다 PubMed search: M1 macrophages anti-tumor activity.
- M2 대식세포는 일반적으로 종양 발생을 촉진하는(pro-tumorigenic) 기능을 수행합니다. 이들은 종양 성장, 혈관신생, 면역억제, 조직 리모델링 및 전이를 지원하는 것으로 알려져 있습니다. M2 하위 유형(M2A, M2B, M2C, M2D)은 서로 다른 활성화 경로와 기능을 가지지만, 전반적으로 종양 친화적인 환경 조성에 기여합니다 PubMed search: M2 macrophages tumor microenvironment.
- M2A는 조직 복구 및 면역 억제에 주로 관여하며, 항원 제시를 억제하고 Th2 반응을 유도할 수 있습니다.
- M2B는 면역 조절에 관여하며, 염증 및 항염증 사이토카인을 모두 생성할 수 있습니다.
- M2C는 염증 해소 및 면역 억제에 중요하며, 주로 IL-10과 TGF-$\beta$를 분비합니다.
- M2D는 종양 관련 대식세포(TAM)의 주요 하위 유형으로 간주되며, 혈관신생과 전이를 강력하게 촉진합니다.
이 분석 결과에서 종양 조직 내 M2A 및 M2B 대식세포의 상대적인 증가는 대장암 미세환경이 면역억제적이고 종양 촉진적인 방향으로 변화하고 있음을 시사합니다. 이는 종양 세포가 대식세포를 M2형으로 재프로그래밍하여 자신의 성장에 유리한 환경을 조성하는 일반적인 현상과 일치합니다. 대장암 맥락에서 M2형 대식세포의 증가는 불량한 예후와 관련이 있는 경우가 많습니다.
Clinical or Translational Implications
- 예후 및 치료 반응 바이오마커: 종양 미세환경 내 M2A 및 M2B 대식세포의 비율 증가는 대장암 환자의 불량한 예후와 관련될 수 있으며, 특정 치료(예: 면역관문억제제)에 대한 반응을 예측하는 바이오마커로 활용될 가능성이 있습니다.
- 치료 표적: M2형 대식세포의 활성화를 억제하거나, 이들을 M1형으로 재극성화(repolarization)하는 전략은 대장암 치료의 새로운 접근 방식이 될 수 있습니다 PubMed search: targeting M2 macrophages cancer therapy. 특히 M2A 및 M2B의 특정 활성화 경로를 표적하는 약물 개발이 고려될 수 있습니다.
- 환자 맞춤형 치료: 환자 간 대식세포 하위 유형 구성의 이질성은 개인화된 암 치료 전략의 필요성을 강조합니다. 특정 환자의 종양 미세환경에서 우세한 대식세포 하위 유형을 식별함으로써, 보다 효과적인 면역 치료법을 선택하거나 개발할 수 있습니다.
10. Macrophage Subset Population Shifts in Colon Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigated the proportional representation of specific Macrophage subset populations (identified at the celltype_subset level) in single-cell RNA-seq data from human Colon tissue. The objective was to identify macrophage subsets that exhibit significant differences in their proportions when comparing tumor tissues to adjacent normal tissues. The comparison was performed using a statistical test with a p-value cutoff of 0.1 and a log2 fold change cutoff of 0.1.
Visual Summary
The boxplots illustrate the proportions of two Macrophage subsets, Mac (M1) and Mac (M2B), across 'tumor' and 'adjacent_normal' conditions. Each point represents a sample's proportion of that specific macrophage subset, with the box showing the interquartile range and the line indicating the median.
- Mac (M1): This subset shows a significantly higher median proportion in 'tumor' samples compared to 'adjacent_normal' samples (p ≤ 0.05). The 'tumor' samples have a median M1 proportion of approximately 62-63%, whereas 'adjacent_normal' samples show a median of around 53-54%. This suggests an enrichment of M1-like macrophages within the tumor microenvironment.
- Mac (M2B): Conversely, the Mac (M2B) subset exhibits a lower median proportion in 'tumor' samples compared to 'adjacent_normal' samples (p = 0.08). The median M2B proportion in 'tumor' is approximately 14-15%, while in 'adjacent_normal' it is around 20-21%. This indicates a relative decrease or reduced prevalence of M2B macrophages in the tumor compared to the surrounding normal tissue.
Biological Interpretation
Macrophages are highly plastic immune cells that polarize into distinct functional phenotypes, traditionally categorized as M1 (pro-inflammatory, anti-tumorigenic) and M2 (anti-inflammatory, pro-tumorigenic, tissue-repairing) subsets. However, this categorization is an oversimplification, and macrophages can exist on a spectrum with mixed phenotypes, particularly in complex environments like tumors [1, 2].
- Enrichment of Mac (M1) in Tumor: The observed higher proportion of Mac (M1) cells in tumor tissue is noteworthy. M1 macrophages are typically associated with robust anti-tumor immune responses, characterized by the production of pro-inflammatory cytokines (e.g., IL-12, TNF-α) and nitric oxide, leading to direct cytotoxicity against cancer cells [1]. Their increased presence could suggest an active host immune attempt to combat the tumor. However, it's also possible that these M1-like cells in the tumor microenvironment (TME) might be rendered dysfunctional or co-opted by the tumor to support aspects of its growth, or that their activation state is heterogeneous [3]. In some contexts, M1 macrophages can contribute to chronic inflammation that might paradoxically promote tumor progression over time, depending on the specific inflammatory milieu.
- Decreased Mac (M2B) in Tumor: The lower proportion of Mac (M2B) in tumor compared to adjacent normal tissue is an interesting finding. M2B macrophages are a distinct M2 subset, often induced by immune complexes and Toll-like receptor agonists. They are known to produce high levels of IL-6 and TNF-α, cytokines that can have both pro-inflammatory and pro-tumorigenic roles depending on the context [4]. A reduction in this specific M2 subset within the tumor might indicate a shift in the overall M2 polarization landscape, where other M2 subtypes (e.g., M2A, M2C, M2D, which are also present in celltype_subset) might be more dominant or actively recruited, or that M2B are less critical for tumor progression in this specific colon cancer context compared to their role in adjacent tissue homeostasis or early neoplastic changes.
These findings suggest a complex and dynamic macrophage landscape in the colon TME. The concurrent increase in M1 and decrease in M2B macrophages imply a nuanced immune response that deviates from a simple M1 depletion/M2 enrichment model often generalized in cancer. The specific balance and functional state of these macrophage subsets likely contribute to the overall immune contexture of colon cancer.
Clinical or Translational Implications
Understanding the precise shifts in macrophage subsets within the colon tumor microenvironment has significant clinical and translational implications:
- Prognosis and Biomarkers: The proportions of M1 and M2B macrophages could serve as prognostic biomarkers in colon cancer. For example, a higher M1/M2B ratio within the tumor might correlate with a better patient outcome, or vice versa. Further studies correlating these proportions with clinical data (e.g., tumor stage, treatment response, survival) are warranted.
- Immunotherapy Targets: Macrophages are key targets for cancer immunotherapy [5].
- If the M1 macrophages in the tumor are truly anti-tumorigenic but perhaps suppressed, strategies to enhance their activation and effector functions (e.g., via TLR agonists or CD40 agonists) could be explored.
- Conversely, if the lower proportion of M2B in the tumor suggests a less pro-tumorigenic environment driven by this specific subset, understanding the mechanisms behind this reduction could provide insights into preventing M2B recruitment or polarization.
- Drug Development: Detailed knowledge of macrophage subset distribution and function can guide the development of targeted therapies. For instance, drugs that modulate macrophage polarization away from pro-tumorigenic phenotypes (e.g., other M2 subtypes not explicitly shown here but potentially present) and towards M1-like functions are under active investigation.
These results highlight the necessity of deep phenotyping of immune cell subsets to unravel the intricate interactions within the tumor microenvironment and inform precision oncology approaches.
---
References
- M1/M2 Macrophage Polarization: Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo experience with cytokines. *Semin Immunol*. 2012 Oct;24(5):367-75. PubMed search link
- Macrophages in Cancer: Rhee I. The Immune Landscape of Cancer: Macrophages. *Cancers (Basel)*. 2024 Jan 12;16(2):331. PubMed search link
- Tumor-associated Macrophages (TAMs) Plasticity: Guc E, Ozturk Z, Uysal-Sevimli N, Sivas H. The multifaceted roles of tumor-associated macrophages in cancer. *Cell Biosci*. 2023 Mar 1;13(1):37. PubMed search link
- M2B Macrophages: Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical and Functional Differences. *Front Immunol*. 2014 Sep 9;5:514. PubMed search link
- Macrophage-targeted Immunotherapy: De Palma M, Lewis CE. Macrophage Regulation of Tumor Responses to Immunotherapy. *Cancer Cell*. 2020 Mar 16;37(3):323-336. PubMed search link
11. Ploidy Population Analysis of Intestinal Epithelial and Unassigned Cells in Colorectal Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a barplot showing the relative proportions of Aneuploid, Diploid, and Unclear cells within the 'Intestinal Epithelial cell' and 'unassigned' populations for individual samples. These proportions are separately visualized for 'adjacent_normal' and 'tumor' conditions. Given that 'Intestinal Epithelial cell' is identified as the tumor origin cell type, this analysis provides insight into the genomic stability of the presumed malignant cells and potentially difficult-to-classify cells across disease states.
Visual Summary
The visualization consists of two barplots, one for 'adjacent_normal' samples and another for 'tumor' samples. Each bar represents a distinct sample, and the bar segments indicate the percentage of cells classified as Aneuploid (dark red), Diploid (orange), or Unclear (light green) within the combined 'Intestinal Epithelial cell' and 'unassigned' populations.
- Adjacent Normal Samples: Most adjacent normal samples show a predominant Diploid population, often exceeding 90%. However, a notable subset of adjacent normal samples (e.g., C154, C203, C204, C206, C191, C211, C213, C220) exhibit a substantial proportion of Aneuploid cells, ranging from approximately 20% to over 60%. The 'Unclear' category is generally a minor component, typically less than 10%.
- Tumor Samples: In comparison to adjacent normal tissue, tumor samples generally display a higher prevalence of Aneuploid cells. Many tumor samples (e.g., C154, C203, C204, C206, C211, C213, C220, C191, C207, C209, C219) show significant Aneuploidy, with some samples having Aneuploid cells making up over 90% of the combined 'Intestinal Epithelial cell' and 'unassigned' populations. However, there is considerable heterogeneity among tumor samples; several samples (e.g., C192, C194, C196, C197, C198, C199, C200, C201, C202, C208, C210, C212, C214, C215, C216, C217, C218, C221, C222, C223) still appear predominantly Diploid, similar to healthy tissue. The 'Unclear' population remains minor across most tumor samples.
- Sample-Specific Patterns: There are individual samples, like C154, C203, C204, C206, C211, C213, C220, C191, that show high Aneuploidy in both adjacent normal and tumor conditions. This indicates potential field cancerization or pre-existing genomic instability, or perhaps tumor cell contamination even in the 'adjacent normal' biopsies.
Biological Interpretation
Aneuploidy, characterized by an abnormal number of chromosomes, is a hallmark of cancer and a direct indicator of genomic instability [1]. In this context, the observation of Aneuploid cells specifically within the 'Intestinal Epithelial cell' population—designated as the tumor origin cell type—strongly supports their malignant transformation and cancerous nature.
- Tumor vs. Adjacent Normal Differences: The general increase in aneuploidy from adjacent normal to tumor conditions within the 'Intestinal Epithelial cell' and 'unassigned' populations is consistent with oncogenic progression in colorectal cancer. This genomic instability drives tumor evolution and heterogeneity.
- Heterogeneity in Aneuploidy: The significant sample-to-sample variability in aneuploidy percentages, even within tumor samples, suggests substantial biological heterogeneity among different tumors. Some tumors might harbor predominantly diploid cancer cells, or single-cell sequencing might have captured a higher proportion of non-aneuploid stromal/immune cells mistakenly classified as "unassigned" in certain samples, or the tumor itself might be less aneuploid (e.g., some microsatellite instability-high tumors can be diploid). Conversely, samples with high aneuploidy likely represent highly chromosomally unstable tumors.
- Aneuploidy in "Adjacent Normal": The presence of Aneuploid 'Intestinal Epithelial cells' and 'unassigned' cells in seemingly "adjacent normal" tissues from some patients is a crucial finding. This could indicate:
- Field Cancerization: The presence of molecular changes, including genomic instability, in histologically normal-appearing tissue surrounding a tumor, which increases the risk of recurrence or new tumor development [2].
- Early Oncogenic Events: These aneuploid cells might represent early stages of malignant transformation that are not yet histologically apparent.
- Sampling Bias/Contamination: While less likely for single-cell data due to precise cell sorting, some degree of microscopic tumor cell contamination cannot be entirely ruled out in the adjacent normal biopsies.
- Significance of "Unassigned" Cells: If 'unassigned' cells within tumor samples also show high aneuploidy, it implies that these cells, despite lacking clear minor cell type markers, share a key genomic feature of malignant cells, suggesting they might indeed be tumor cells or tumor-associated cells that are difficult to classify.
Clinical or Translational Implications
- Biomarker for Malignancy: Aneuploidy in 'Intestinal Epithelial cells' serves as a robust marker for identifying malignant cells, which is particularly useful for distinguishing true tumor cells from other stromal or immune cells in the tumor microenvironment.
- Prognostic Value: The degree of aneuploidy is often associated with tumor aggressiveness and patient prognosis in various cancers [3]. Tumors with higher aneuploidy might correlate with more aggressive disease or resistance to certain therapies.
- Identifying High-Risk Adjacent Tissue: The detection of aneuploid cells in adjacent normal tissue could help identify patients at higher risk for recurrence or progression, suggesting a need for more aggressive surveillance or preventative strategies.
- Guiding Therapy: Understanding the genomic instability profiles of individual tumors could potentially inform treatment decisions, as highly aneuploid tumors might respond differently to chemotherapy or targeted therapies compared to diploid tumors.
References
- Aneuploidy as a hallmark of cancer: PubMed search: aneuploidy cancer hallmark genomic instability
- Field Cancerization: PubMed search: field cancerization colorectal cancer
- Aneuploidy and Prognosis: PubMed search: aneuploidy cancer prognosis
12. Cell-Cell Interaction Patterns in the Colon Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the cell-cell interaction (CCI) landscape within the tumor microenvironment of human colon tissue using single-cell RNA-seq data. The CellPhoneDB method was applied to identify significant ligand-receptor interactions between specific cell types: Intestinal Epithelial cells (including the tumor origin population), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+). The results are presented as a dot plot, highlighting the top 80 most significant interactions in the tumor condition, based on p-value and mean expression cutoffs. The expand_ploidy_from_tumor_origin parameter allowed for distinguishing between different ploidy states for the tumor origin cell type.
Visual Summary
The dot plot visualizes the strength and significance of cell-cell interactions in the tumor condition.
- Axes: The y-axis lists interacting cell type pairs, where the first cell type expresses the ligand and the second expresses the receptor (or vice versa, as CellPhoneDB often treats interactions symmetrically for visualization, but the tool here uses swap_ax=True for better readability, implying CellA|CellB where CellA is the sender and CellB is the receiver, or vice versa if the interaction is bidirectional). The x-axis represents specific ligand-receptor gene pairs.
- Dot Size: The size of each dot is inversely proportional to the interaction's p-value (-log10(p)), meaning larger dots indicate more statistically significant interactions.
- Dot Color: The color of each dot represents the log2-transformed mean expression of the interacting ligand-receptor pair, with brighter colors (yellow/green) indicating higher mean expression and darker colors (purple/blue) indicating lower expression.
- Dominant Cell Pairs: The most prominent interactions involve Macrophages (Mac), T cells (T CD4+, T CD8+), and Diploid Intestinal Epi cells. Notably, interactions between Macrophages and Diploid Intestinal Epithelial cells (Mac|Diploid Intestinal Epi and Diploid Intestinal Epi|Mac) appear frequently and with high significance/expression. Interactions among immune cells (Mac|Mac, T CD4+|T CD4+, T CD8+|T CD8+, T CD8+|Mac, T CD4+|Mac, T CD4+|T CD8+) are also abundant.
- Key Ligand-Receptor Interactions: Several ligand-receptor pairs show strong and frequent interactions across various cell types. These include APOE_TREM2_receptor, CD40LG-CD40, CD86-CD28, LAGLS9-HAVCR2, SPP1_integrin_a4b1_complex, THBS1_integrin_a3b1_complex, VSIR-HLA-E, CXCL16-CXCR6, and HBEGF-ERBB2.
- Observation on Target Cells: Despite being included in the target_cells list, interactions involving 'Fibroblast' and explicitly 'Aneuploid Intestinal Epithelial cell' (which would represent the malignant tumor origin cells) are not present within the top 80 displayed interactions. The epithelial cell interactions shown are exclusively from Diploid Intestinal Epi. This suggests that for the stringent criteria (top 80, pval < 0.05, mean > 0.01), these specific cell types either had fewer strong interactions or their interactions were less significant than those shown.
Biological Interpretation
The analysis highlights a dynamic and complex intercellular communication network within the colon tumor microenvironment, primarily driven by immune cells (Macrophages and T cells) and non-malignant (Diploid) Intestinal Epithelial cells.
- Dominance of Immune-Immune and Immune-Diploid Epithelial Interactions: The observed interactions suggest intense crosstalk among immune cells, crucial for orchestrating immune responses, and between immune cells and the resident non-malignant epithelial compartment. The frequent interactions involving Diploid Intestinal Epi cells indicate their active role in shaping the tumor microenvironment, even if they are not the malignant clone. These cells could be involved in maintaining tissue homeostasis, responding to inflammation, or providing signals that influence the adjacent tumor and immune cells.
- Key Immune Modulatory Interactions:
- Co-stimulation/Co-inhibition: High levels of CD86-CD28 (Mac|T CD4+) and CD40LG-CD40 (T CD4+|Mac) signaling indicate active T cell-macrophage interactions, essential for T cell activation and antigen presentation. Conversely, LAGLS9-HAVCR2 (Galectin-9/TIM-3) interactions between T cells and macrophages, and VSIR-HLA-E (VISTA/HLA-E) interactions between T CD8+ cells and Diploid Intestinal Epithelial cells, suggest potential immune suppressive mechanisms. TIM-3/Galectin-9 is a well-known immune checkpoint associated with T cell exhaustion in cancer [1]. VISTA (VSIR) is also a negative regulator of T cell activation and function, and its interaction with HLA-E on epithelial cells could contribute to immune evasion or dampening [2].
- Chemokine Signaling: CXCL16-CXCR6 (Mac|T CD8+) suggests recruitment of CXCR6-expressing T cells by CXCL16-producing macrophages, which can be critical for anti-tumor immunity or, depending on the context, could also support pro-tumor functions. CCL5-CCR1 and CCL15-CCR1 also indicate chemokine-mediated recruitment and activation of immune cells.
- Adhesion and ECM Remodeling: Interactions involving SPP1_integrin_a4b1_complex and THBS1_integrin_a3b1_complex (both Mac|Diploid Intestinal Epi) highlight the role of macrophages and non-malignant epithelial cells in modulating the extracellular matrix. SPP1 (Osteopontin) is often associated with pro-tumor functions, including immune cell recruitment, metastasis, and angiogenesis [3]. THBS1 (Thrombospondin-1) can regulate angiogenesis and immune cell function, often with context-dependent roles in cancer [4].
- Metabolic and Growth Factor Signaling: The APOE_TREM2_receptor interaction (Mac|Diploid Intestinal Epi) suggests lipid metabolism and sensing in the tumor microenvironment. TREM2 on macrophages is involved in lipid metabolism and has complex roles in cancer, sometimes promoting tumor growth by fostering an immunosuppressive environment [5]. HBEGF-ERBB2 interactions (Mac|Diploid Intestinal Epi) indicate potential growth factor signaling that could influence cell proliferation and survival.
- Implications of Absent Cell Types: The absence of interactions involving Fibroblast and specifically the Aneuploid Intestinal Epithelial cell (malignant tumor cells) within the top 80 most significant pairs is a notable finding. This does not mean these cells are inactive, but rather that their highly significant, high-expression interactions are less prominent than the immune-immune and immune-diploid epithelial cell interactions identified under the chosen criteria. It might imply that while malignant epithelial cells certainly interact, their strongest single ligand-receptor events might be diluted, less frequent, or have lower mean expression compared to the observed immune and non-malignant epithelial crosstalk. This could also suggest that the dominant influences on immune cells within the tumor microenvironment, at the level of specific ligand-receptor pairs, come from other immune cells and the non-malignant epithelial component.
Clinical or Translational Implications
The identified cell-cell interactions offer several avenues for clinical and translational exploration in colon cancer:
- Therapeutic Target Prioritization:
- Immune Checkpoints: The prominent LAGLS9-HAVCR2 (Galectin-9/TIM-3) and VSIR-HLA-E (VISTA/HLA-E) interactions represent potential targets for immunotherapeutic intervention. Blocking these pathways could reinvigorate T cell activity against tumor cells or modulate the immunosuppressive microenvironment. Inhibitors targeting TIM-3 are currently under investigation [6].
- Pro-tumor Signaling: Interactions like APOE-TREM2_receptor and SPP1-integrin_a4b1_complex involving macrophages and diploid epithelial cells suggest pathways that might promote tumor progression or immune evasion. Targeting TREM2 or SPP1 could be explored to alter macrophage polarization or reduce tumor-supportive signaling [7].
- Growth Factors: The HBEGF-ERBB2 axis indicates potential proliferative signals, which could be targeted with existing ERBB2 inhibitors, although the specific cell types involved (Macrophage and Diploid Intestinal Epi) suggest complex paracrine signaling rather than direct tumor cell proliferation.
- Biomarker Discovery: The identified highly significant ligand-receptor pairs, particularly those involved in immune modulation, could serve as biomarkers for patient stratification, response to immunotherapy, or prognosis. For example, the expression levels of Galectin-9, TIM-3, VISTA, or their co-expression patterns in specific cell populations might predict patient outcomes.
- Experimental Validation: The specific cell-cell and ligand-receptor pairs identified provide clear hypotheses for further experimental validation. In vitro co-culture experiments, organoid models, or in vivo genetic manipulation in mouse models could be used to confirm the functional relevance of these interactions in colon cancer progression and immune response. For instance, investigating the impact of blocking LAGLS9 on T cell exhaustion in the context of T CD4+|Mac interactions could be a critical next step.
- Understanding Tumor Microenvironment Complexity: The emphasis on interactions between immune cells and non-malignant epithelial cells underscores the importance of the entire tumor microenvironment, not just the malignant cells, in disease progression. Therapeutic strategies might need to consider modulating the stromal and immune components that directly interact with both malignant and non-malignant tissue components.
---
References:
[1] Galectin-9/TIM-3 pathway: A PubMed search for "TIM-3 Galectin-9 cancer immunotherapy" will yield many relevant papers. https://pubmed.ncbi.nlm.nih.gov/?term=TIM-3+Galectin-9+cancer+immunotherapy
[2] VISTA (VSIR): GeneCards entry for VSIR. https://www.genecards.org/cgi-bin/carddisp.pl?gene=VSIR
[3] SPP1 (Osteopontin): GeneCards entry for SPP1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPP1
[4] THBS1 (Thrombospondin-1): GeneCards entry for THBS1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=THBS1
[5] TREM2: A PubMed search for "TREM2 cancer" can provide context. https://pubmed.ncbi.nlm.nih.gov/?term=TREM2+cancer
[6] TIM-3 inhibitors: A PubMed search for "TIM-3 inhibitor clinical trial" will show current developments. https://pubmed.ncbi.nlm.nih.gov/?term=TIM-3+inhibitor+clinical+trial
[7] Targeting TREM2 in cancer: A PubMed search for "targeting TREM2 cancer" can provide information. https://pubmed.ncbi.nlm.nih.gov/?term=targeting+TREM2+cancer
13. Condition-Specific Cell-Cell Interaction Patterns in Colon Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB results, comparing 'adjacent_normal' and 'tumor' conditions in human colon tissue. The visualization displays the standardized mean interaction strength (color intensity) and significance (-log10(p-value), dot size) for selected ligand-receptor pairs between specific cell types across individual samples, allowing for a detailed examination of how cell communication networks are altered in the tumor microenvironment. The plot_dot_for_cci_with_signif_difference tool was used to highlight interactions showing significant differences between conditions.
Visual Summary
The dot plot is organized into two main panels: 'adjacent_normal' (left) and 'tumor' (right). Each row represents a sample, and each column represents a unique cell-cell interaction (CCI Index), defined by a ligand-receptor pair and the interacting cell types.
- Differential Activation: There is a clear and distinct shift in CCI patterns between adjacent normal and tumor tissues. Many interactions that are prominent (darker red, larger dots) in the 'adjacent_normal' samples become attenuated or absent in 'tumor' samples, and vice versa.
- Adjacent Normal Dominant Interactions: In the 'adjacent_normal' panel, a diverse set of interactions appears active across many samples. Notably, interactions involving Diploid Intestinal Epithelial cells (Ent.Epi(Dip)) with various immune and stromal cells (e.g., Macrophages, T cells, Endothelial cells) are frequently observed. Examples include ProstaglandinE2_byPTGES3-Mac and Ent.Epi(Dip), CXCL12_CXCR4-Ent.Epi(Dip).
- Tumor Dominant Interactions: The 'tumor' panel reveals a strong activation of a different set of interactions. A striking pattern is the high prevalence and strength of interactions involving Aneuploid Intestinal Epithelial cells (Ent.Epi(Aneup)), which are likely the malignant epithelial cells, with components of the tumor microenvironment such as Macrophages, Fibroblasts, and Endothelial cells. These interactions often show high intensity (dark red) and significance (large dots) across many tumor samples, particularly in a large cluster towards the right side of the plot.
- Key Tumor-Associated Interactions: Prominent tumor-specific interactions include:
- Extracellular Matrix (ECM) Remodeling & Adhesion: Interactions involving SPP1 (Osteopontin), FN1 (Fibronectin), COL4A1, COL6A2 with various integrin receptors (e.g., SPP1_integrin_aVb3_complex-Mac|Ent.Epi(Aneup)) are highly activated in tumors. These frequently involve Ent.Epi(Aneup), Macrophage, and Fibroblast cells.
- Growth Factors & Angiogenesis: VEGFA_FLT1 (VEGF-A and its receptor FLT1) interactions are notably strong in tumor, often involving Endothelial cell and Macrophage.
- Immune Modulation & Signaling: TGFB1_TGFbeta_receptor1 interactions are activated in tumors, often involving Fibroblast, Endothelial cell, and T cell CD4+. JAG2_NOTCH3 interactions, involving Fibroblast and Endothelial cell, also show increased activity.
- Inflammation & Immune Cell Engagement: ICAM1_integrin, ICAM3_integrin interactions are frequently observed with Ent.Epi(Aneup), Macrophage, and T cell CD8+ in tumor samples.
Biological Interpretation
The observed differential CCI patterns provide critical insights into the distinct cellular crosstalk underlying colon tissue homeostasis versus tumor progression.
- Role of Ploidy in Tumor-Specific Interactions: The most striking biological insight is the shift in interaction partners driven by the ploidy status of Intestinal Epithelial cells. Diploid epithelial cells (Ent.Epi(Dip)) are central to interactions in normal tissue, likely supporting tissue integrity and baseline immune surveillance. In contrast, Aneuploid epithelial cells (Ent.Epi(Aneup)), representing the malignant cell population, become major players in the tumor microenvironment, initiating and responding to a new repertoire of interactions. This highlights the tumor cells themselves as active architects of their niche.
- Normal Tissue Homeostasis: The interactions observed in adjacent normal tissue likely represent mechanisms for maintaining epithelial barrier function, tissue repair, and balanced immune responses. For instance, ProstaglandinE2 signaling often plays roles in local inflammation and epithelial regeneration PubMed search: Prostaglandin E2 epithelial homeostasis. CXCL12-CXCR4 signaling is crucial for immune cell trafficking and tissue development GeneCards: CXCL12.
- Tumor Microenvironment Remodeling: The highly active interactions in tumor tissue point towards established hallmarks of cancer:
- ECM Remodeling and Metastasis: The prominence of SPP1, FN1, and COL family interactions with integrins indicates extensive extracellular matrix (ECM) remodeling. SPP1 (Osteopontin) is a multifunctional cytokine often overexpressed in various cancers, promoting cell adhesion, migration, and survival, and is associated with tumor progression and metastasis GeneCards: SPP1. Fibronectin and collagens are key components of the ECM that are reorganized to facilitate tumor invasion and angiogenesis PubMed search: ECM remodeling cancer.
- Angiogenesis: The strong VEGFA_FLT1 signaling is a direct indicator of active angiogenesis, the formation of new blood vessels, which is essential for tumor growth and metastasis by supplying nutrients and oxygen PubMed search: VEGFA angiogenesis cancer.
- Immune Evasion and Stromal Activation: TGFB1_TGFbeta_receptor1 signaling is a potent immunosuppressive pathway in the tumor microenvironment, promoting tumor cell proliferation, epithelial-mesenchymal transition (EMT), and dampening anti-tumor immune responses PubMed search: TGFB1 cancer immunosuppression. The involvement of Fibroblast cells in these interactions suggests activated cancer-associated fibroblasts (CAFs) actively contributing to tumor progression.
- Notch Signaling: JAG2_NOTCH3 interactions highlight the activation of Notch signaling, which plays diverse roles in cancer, including cell proliferation, survival, angiogenesis, and stem cell maintenance PubMed search: Notch signaling cancer.
- Macrophage Reprogramming: The consistent involvement of Macrophages in tumor-specific interactions, often with Ent.Epi(Aneup), suggests a shift towards pro-tumorigenic macrophage phenotypes (e.g., M2-like polarization) that support tumor growth and immune suppression, contrasting with potential immune surveillance roles in normal tissue.
Clinical or Translational Implications
- Biomarker Discovery: The identified tumor-specific CCI pairs, particularly those involving Aneuploid Intestinal Epithelial cells, could serve as novel diagnostic or prognostic biomarkers for colon cancer progression and microenvironment status.
- Therapeutic Targeting: Many of the highly active CCIs in the tumor microenvironment represent promising therapeutic targets.
- Targeting SPP1-integrin or other ECM-related adhesion pathways could inhibit tumor cell migration and invasion.
- Inhibiting VEGFA-FLT1 signaling is a well-established strategy in cancer therapy to suppress angiogenesis.
- Blocking TGFB1 signaling could reverse immunosuppression and enhance anti-tumor immunity.
- Modulating Notch signaling, while complex, could disrupt tumor-stroma communication vital for tumor growth.
- Combination Therapies: Given the multifaceted nature of tumor-stroma interactions, combination therapies targeting multiple key CCI pathways (e.g., angiogenesis + immune suppression) may yield more effective clinical outcomes.
- Understanding Aneuploid Cell Behavior: Further investigation into how aneuploid epithelial cells specifically modulate their secretome and receptor expression to establish these pro-tumorigenic interactions is crucial for understanding cancer biology and developing targeted treatments.
14. Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Colorectal Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) using CellPhoneDB for a curated list of genes associated with immune checkpoint and cell cycle pathways. The CCI results are presented for two conditions: "adjacent_normal" and "tumor" tissue from human colon single-cell RNA-seq data. The goal is to identify specific ligand-receptor pairs and cellular interactions that are differentially active between normal and tumor microenvironments, with a focus on understanding immune regulation and cellular proliferation within colorectal cancer. The plot_cci_dots tool visualizes the significance (p-value, dot size) and interaction strength (mean expression, dot color) for identified ligand-receptor pairs across various cell-cell type combinations.
Visual Summary
The provided dot plots illustrate cell-cell interactions for selected immune checkpoint and cell cycle-related genes, comparing the adjacent normal tissue to the tumor microenvironment.
Adjacent Normal Tissue
- Key Interacting Pairs: T cells (CD8+ and CD4+) show significant autocrine/paracrine interactions (e.g., T CD8+|T CD8+) and heterotypic interactions with Macrophages (T CD8+|Mac, T CD4+|Mac). Macrophage-Macrophage (Mac|Mac) interactions are also observed.
- Epithelial Involvement: A notable interaction between Macrophages and Diploid Intestinal Epithelial cells (Mac|Diploid Intestinal Epi) is present, specifically through the CD86-CD28 co-stimulatory pathway.
- Dominant Signals: Strong IFN-gamma signaling (IFNG-Type II IFN receptor) and LCK-CD8 receptor interactions are prominent among T cells and between T cells and Macrophages, indicating active immune surveillance.
- Immunosuppressive Signals: TGFB1-TGFbeta_receptor1 interactions are also detected, particularly within Macrophages (Mac|Mac) and between Macrophages and T cells (T CD4+|Mac, T CD8+|Mac), suggesting a baseline level of immune modulation.
- Cell Cycle related: Interactions involving HBEGF-EGFR are present but show relatively low mean expression and significance, suggesting they are not primary drivers in these specific cell-cell contexts.
Tumor Microenvironment
- Increased Interaction Strength and Significance: Compared to adjacent normal tissue, the tumor microenvironment generally exhibits higher mean expression values (darker colors) and often stronger statistical significance (larger dot sizes) for most identified interactions. This indicates an intensified and dysregulated communication landscape.
- Loss of Epithelial Interaction: The Mac|Diploid Intestinal Epi interaction, notably involving CD86-CD28, is absent in the tumor plot. This suggests a shift in the interacting epithelial cell population (e.g., from diploid normal to aneuploid tumor cells) or altered interaction profiles of immune cells with tumor epithelial cells.
Heightened Immune Signaling:
- IFN-gamma signaling (IFNG-Type II IFN receptor) is markedly strong across T cell and Macrophage interactions (e.g., T CD8+|T CD8+, T CD8+|Mac), indicating a robust, albeit potentially ineffective, immune response.
- LCK-CD8 receptor interactions are also intensified, reflecting elevated CD8+ T cell activity.
- CD86-CD28 co-stimulatory interactions between T cells and Macrophages are strengthened, pointing to increased T cell activation potential by antigen-presenting cells (APCs).
- Amplified Immunosuppressive Signaling: TGFB1-TGFbeta_receptor1 interactions are significantly stronger, especially within Macrophages (Mac|Mac) and from Macrophages to T cells (T CD4+|Mac, T CD8+|Mac). This points to an enhanced immunosuppressive environment driven by Macrophages.
- HBEGF-EGFR: Remains low in activity, similar to the normal condition.
Biological Interpretation
The analysis reveals a dynamic and drastically altered cell-cell communication landscape in the colorectal tumor microenvironment compared to adjacent normal tissue, particularly concerning immune checkpoint and T cell activation pathways.
- Shift in Macrophage-Epithelial Interactions: The disappearance of CD86-CD28 interactions between Macrophages and "Diploid Intestinal Epi" cells in the tumor context is highly significant. Given that the tumor's origin cell type is "Intestinal Epithelial cell" and ploidy inference labels (Aneuploid/Diploid) are available, this suggests that the normal diploid epithelial cells are either less prominent in the tumor or their interaction profile with macrophages changes drastically. Tumor epithelial cells are typically aneuploid and often evade immune recognition and costimulation.
- Dual Nature of Immune Activity:
- Pro-inflammatory/Anti-tumor Signals: The intensified IFN-gamma signaling from T cells and its reception by T cells and Macrophages in the tumor implies an active, pro-inflammatory immune response. IFN-gamma is a critical cytokine for anti-tumor immunity, stimulating antigen presentation and T cell activation [Ref: GeneCards for IFNG: GeneCards]. Similarly, the robust LCK-CD8 receptor interactions reflect the presence and engagement of CD8+ cytotoxic T lymphocytes (CTLs), crucial for direct killing of tumor cells. The stronger CD86-CD28 co-stimulatory interactions suggest increased activation attempts by APCs (macrophages) towards T cells.
- Immunosuppressive Counter-signals: Concurrently, there is a striking upregulation of TGFB1-TGFbeta_receptor1 signaling by macrophages in the tumor. TGF-beta is a potent immunosuppressive cytokine that can inhibit T cell proliferation and function, promote regulatory T cell (Treg) development, and foster an M2-like phenotype in macrophages, thereby promoting tumor growth and metastasis [Ref: PubMed search for "TGFB tumor immunosuppression" PubMed Search]. This suggests that despite the heightened pro-inflammatory signals, the tumor microenvironment effectively co-opts macrophages to establish a robust immunosuppressive shield.
- Role of Macrophages: Macrophages appear as central players, mediating both pro-inflammatory (via CD86-CD28) and predominantly immunosuppressive (via TGFB1-TGFbeta_receptor1) interactions with T cells and within their own population. The observed changes are consistent with the known plasticity of tumor-associated macrophages (TAMs), which often adopt an M2-like, pro-tumor phenotype in the TME.
- Limited Cell Cycle Direct Interactions: While many cell cycle genes were included in the target_genes list, only ligand-receptor pairs like HBEGF-EGFR, which can influence cell proliferation, were captured in the CCI plot. The low activity of HBEGF-EGFR suggests other growth factors or intracellular pathways are more dominant in driving proliferation or these interactions are not prominent in the displayed cell-cell pairs.
Clinical or Translational Implications
The findings have significant implications for understanding colorectal cancer progression and developing therapeutic strategies.
- Therapeutic Targets for Immunosuppression: The pronounced TGFB1-TGFbeta_receptor1 signaling from macrophages in the tumor microenvironment presents a strong candidate for therapeutic intervention. Targeting the TGF-beta pathway, either by inhibiting TGF-beta ligands or their receptors, could potentially reverse macrophage-mediated immunosuppression and enhance anti-tumor T cell responses. Such strategies could be particularly beneficial in combination with other immunotherapies.
- Macrophage Reprogramming: The central role of macrophages in mediating both activating and suppressive signals suggests that strategies aimed at reprogramming tumor-associated macrophages (TAMs) from a pro-tumor (M2-like) to an anti-tumor (M1-like) phenotype could be highly effective. Modulating costimulatory pathways, while also addressing immunosuppressive mechanisms, is crucial for effective anti-tumor immunity.
- Biomarker Potential: The differential patterns of CCI, particularly the balance between pro-inflammatory (IFN-gamma, CD86-CD28) and immunosuppressive (TGFB1) interactions, could serve as biomarkers to predict patient response to immunotherapies or to stratify patients based on the immune landscape of their tumors.
- Understanding Immune Evasion: The simultaneous increase in both pro-inflammatory and immunosuppressive signals highlights the complex mechanisms of immune evasion employed by tumors. While T cells mount an attack (evidenced by IFN-gamma and LCK-CD8 activity), the tumor's ability to orchestrate immunosuppression via macrophages (TGFB1) likely creates an environment where effective anti-tumor responses are curtailed. Therapies must address this intricate balance.
15. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates statistically significant differences in cell-cell interactions (CCI) between adjacent normal and tumor conditions in colon tissue, focusing on major immune and stromal cell types, as well as intestinal epithelial cells (including those inferred to be aneuploid, likely representing malignant cells). CellPhoneDB was used to infer ligand-receptor interactions, and these were aggregated and visualized to highlight condition-specific patterns. The dot plot displays interaction strength (standardized mean, color intensity) and statistical significance (-log10(p-value), dot size) for the top 25 differentially significant interactions per group.
Visual Summary
The dot plot clearly differentiates cell-cell interaction patterns between adjacent_normal and tumor conditions.
- Condition Grouping: Samples are separated into adjacent_normal (top block) and tumor (bottom block) conditions, highlighted by blue vertical lines.
- Interaction Signature Shift: There is a distinct shift in the identity and intensity of prominent CCIs from the adjacent_normal samples to the tumor samples. The left half of the plot shows CCIs predominantly active in adjacent_normal, while the right half displays CCIs highly active in tumor.
- Adjacent Normal Patterns: Interactions in adjacent_normal samples appear more heterogeneous across samples. Key interactions often involve Intestinal Epithelial cells (both diploid and aneuploid) and Macrophages, or Endothelial cells and Macrophages.
- Tumor Patterns: The tumor samples exhibit a more concentrated and consistently strong pattern of specific interactions. A large cluster of highly significant and strong interactions is observed, predominantly involving Fibroblasts and Endothelial cells, as well as Macrophages and T cells, and Aneuploid Intestinal Epithelial cells.
- Significance and Strength: In the tumor condition, many CCIs are represented by large, dark red dots, indicating both high statistical significance (low p-value) and strong interaction strength. In adjacent_normal, while some interactions are strong and significant, the overall density and consistency of such signals appear lower compared to the tumor.
Biological Interpretation
The observed differential CCI patterns provide critical insights into the distinct microenvironments of normal and cancerous colon tissue.
In the adjacent_normal microenvironment:
- Immune Regulation and Early Dysplasia: Several interactions involving Macrophages and Intestinal Epithelial cells (especially Ent.Epi (Aneu)) are prominent.
- ProstaglandinE2_byPTGES3__PTGER2--Ent.Epi (Aneu)-|Mac: Prostaglandin E2 (PGE2) signaling. PGE2 can modulate immune responses, but its interaction with aneuploid epithelial cells in "adjacent normal" might indicate early inflammatory changes or stress responses in a potentially pre-neoplastic context.
- GAS6__AXL--Ent.Epi (Aneu)-|Mac: Growth Arrest Specific 6 (GAS6) binding to AXL receptor. This pathway is involved in cell survival, proliferation, and efferocytosis (clearance of apoptotic cells). Its activity with aneuploid epithelial cells could reflect mechanisms handling cellular stress or early dysregulation, or even promoting survival of abnormal cells in seemingly normal tissue. GeneCards: AXL
- CLU_TREM2_receptor--Endo|Mac: Clusterin (CLU) interacting with Triggering Receptor Expressed on Myeloid cells 2 (TREM2). TREM2 is involved in macrophage function, often in response to tissue damage or inflammation. This interaction could reflect tissue homeostasis or early immune surveillance mechanisms. GeneCards: TREM2
- CXCL10__DPP4--Mac|Ent.Epi (Aneu): CXCL10, a pro-inflammatory chemokine, interacting with DPP4 (CD26) on aneuploid epithelial cells. This suggests an ongoing immune response or an attempt to attract immune cells, potentially T cells, to areas with abnormal epithelial cells.
In the tumor microenvironment:
The tumor microenvironment shows a dramatic shift towards interactions that support tumor growth, invasion, angiogenesis, and immune evasion.
- Extracellular Matrix (ECM) Remodeling and Angiogenesis (Endothelial cell - Fibroblast axis): A cluster of highly significant and strong interactions points to extensive stromal reorganization and vascularization.
- Collagen/Laminin-Integrin interactions: Multiple interactions such as COL1A1_integrin_a1b1_complex--Endo|Fib, COL18A1_integrin_a1b1_complex--Endo|Fib, COL6A2_integrin_a1b1_complex--Endo|Fib, and LAMC1_integrin_a2b1_complex--Endo|Fib highlight robust cell-matrix interactions critical for tumor angiogenesis, invasion, and metastatic progression. Integrins facilitate cell adhesion, migration, and signaling within the altered ECM. PubMed search: Integrin cancer angiogenesis
- PDGF Signaling: PDGFA_PDGFRB--Endo|Fib and PDGFD_PDGFRB--Endo|Fib demonstrate activated Platelet-Derived Growth Factor (PDGF) signaling. PDGF is a potent mitogen for fibroblasts and a key regulator of angiogenesis, promoting the recruitment and activation of stromal cells. GeneCards: PDGFRB
- NOTCH Signaling: JAG1_NOTCH1--Endo|Fib and JAG2_NOTCH3--Endo|Fib indicate active NOTCH signaling between endothelial cells and fibroblasts. Notch pathways are crucial for vessel sprouting, maturation, and maintaining endothelial cell identity, playing a significant role in tumor angiogenesis. PubMed search: Notch signaling tumor angiogenesis
- Immune Evasion (Macrophage - T cell CD4+ axis): Crucial immune checkpoint interactions are highly active in the tumor.
- PD-L2/PD-1 axis: PCD1LG2_PDCD1--Mac|T CD4+ (PD-L2 from Macrophages to PD-1 on T CD4+ cells) is a strong signature of immune suppression. This interaction inhibits T cell activation and proliferation, allowing tumor cells to evade immune surveillance. UniProt: PDCD1 (PD-1)
- CD80/CTLA4 axis: CD80_CTLA4--Mac|T CD4+ (CD80 from Macrophages to CTLA4 on T CD4+ cells) is another critical inhibitory checkpoint, leading to T cell anergy or reduced activation. This reinforces the immunosuppressive nature of the tumor microenvironment. UniProt: CTLA4
- Tumor Cell-Driven Interactions (Aneuploid Intestinal Epithelial cell - Macrophage/Fibroblast axis):
- WNT5A Signaling: WNT5A_FZD3_LRP6--Mac|Ent.Epi (Aneu) and WNT5A_FZD3_LRP5--Mac|Ent.Epi (Aneu) show WNT5A signaling from Macrophages to Aneuploid Intestinal Epithelial cells. WNT5A typically activates non-canonical Wnt pathways, often promoting tumor cell migration, invasion, and metastasis in various cancers.
- TGF-beta Signaling: TGFB1_TGFbeta_receptor1--Mac|Ent.Epi (Dip) and TGFB1_TGFbeta_receptor1--Mac|Ent.Epi (Aneu) highlight transforming growth factor beta 1 (TGFB1) signaling from Macrophages to Intestinal Epithelial cells. TGF-beta is a pleiotropic cytokine with complex roles in cancer, including promoting epithelial-mesenchymal transition (EMT), immunosuppression, and fibrosis. GeneCards: TGFB1
- JAG1_NOTCH2--Ent.Epi (Aneu)-|Fib: Aneuploid Intestinal Epithelial cells interacting with Fibroblasts via NOTCH signaling, indicating critical crosstalk between malignant cells and tumor-associated fibroblasts, which can support cancer stemness and tumor progression.
Clinical or Translational Implications
The identified condition-specific CCI patterns have significant clinical and translational implications for colon cancer:
- Biomarkers for Early Detection/Prognosis: The presence of Ent.Epi (Aneu) interacting with immune cells (e.g., via GAS6-AXL, PGE2) in adjacent_normal samples could potentially serve as early indicators of field cancerization or pre-neoplastic changes, warranting closer monitoring.
Therapeutic Targets:
- Immune Checkpoint Blockade: The strong upregulation of PD-L2/PD-1 and CD80/CTLA4 interactions in the tumor microenvironment provides further evidence for the rationale behind current immune checkpoint inhibitor therapies in colon cancer. These interactions could be explored as potential targets for enhancing anti-tumor immunity.
- Stromal Targeting: The extensive Endothelial-Fibroblast interactions (collagen-integrins, PDGF, NOTCH signaling) underscore the importance of the tumor stroma. Targeting these pathways could inhibit angiogenesis, reduce desmoplastic reactions, and potentially impede tumor growth and metastasis. For example, therapies blocking PDGF receptors or Notch signaling could be investigated.
- Wnt and TGF-beta Pathways: The active WNT5A and TGFB1 signaling pathways represent potential targets for inhibiting tumor cell proliferation, invasion, and immune evasion.
- Patient Stratification: The heterogeneity observed in adjacent_normal samples and the distinct patterns in tumor samples suggest that analyzing CCI profiles could help stratify patients based on their tumor microenvironment characteristics, potentially guiding personalized treatment strategies.
- Drug Resistance Mechanisms: Overactive immune checkpoint pathways might also indicate mechanisms of acquired or intrinsic resistance to existing therapies, suggesting combination therapies could be beneficial.
16. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify surfaceome markers that distinguish Intestinal Epithelial cells in tumor conditions from those in adjacent normal colon tissue. Utilizing single-cell RNA sequencing data, a dot plot was generated to visualize the expression patterns of these surfaceome genes across individual samples, stratified by their inferred ploidy status and condition (adjacent normal vs. tumor). The selection of surfaceome markers ensures a focus on proteins accessible on the cell surface, which are of particular interest for therapeutic targeting and diagnostic applications.
Visual Summary
The dot plot effectively visualizes condition-specific surfaceome marker expression within Intestinal Epithelial cells across different samples.
- Structure: The y-axis represents individual samples, with a clear delineation between "Diploid Cxxx" samples (likely representing adjacent normal tissue, characterized by diploid cells) in the upper block and "Cxxx" samples (representing tumor tissue, where aneuploidy is common, though these specific samples are not labeled "Aneuploid") in the lower block. The x-axis lists the identified surfaceome marker genes.
- Dot Characteristics:
- Dot Size: Corresponds to the fraction of cells within a given sample that express the particular gene. Larger dots indicate a higher percentage of expressing cells.
- Dot Color Intensity: Represents the mean expression level of the gene across all cells in that sample. Darker red indicates higher mean expression.
- Key Observation: A striking pattern of differential expression is observed. The lower block (tumor samples, "Cxxx") shows a consistent and strong upregulation of a large panel of surfaceome genes. These genes are characterized by large, dark red dots, indicating high expression in a significant fraction of tumor-derived Intestinal Epithelial cells. In contrast, the corresponding expression for most of these genes in the upper block (adjacent normal samples, "Diploid Cxxx") is very low or absent (small, light red, or white dots). This visually confirms that these genes serve as strong condition-specific markers, predominantly expressed in the tumor context.
Biological Interpretation
The identified surfaceome markers show a clear enrichment in Intestinal Epithelial cells from tumor samples, suggesting their involvement in the unique biology of colorectal cancer. Several prominent markers stand out:
- CEACAM1 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1): This gene is highly expressed in tumor Intestinal Epithelial cells. CEACAM1 is a well-established oncofetal protein often overexpressed in various cancers, including colorectal cancer. It plays roles in cell adhesion, growth, differentiation, and immune modulation, frequently promoting tumor progression and metastasis. GeneCards: CEACAM1
- ADGRE5 (Adhesion G Protein-Coupled Receptor E5, also known as CD97): Shows strong expression in tumor cells. ADGRE5 is an adhesion G-protein coupled receptor implicated in cell adhesion, migration, and angiogenesis. Its overexpression is associated with tumor growth, invasion, and metastasis in several cancer types, including colorectal cancer. GeneCards: ADGRE5
- ITGA2 (Integrin Alpha-2, also known as CD49b): This integrin subunit is highly expressed in tumor cells. Integrins are crucial cell surface receptors involved in cell-extracellular matrix and cell-cell interactions, mediating processes like cell adhesion, migration, and signaling, all of which are critical for cancer progression. GeneCards: ITGA2
- EREG (Epiregulin): A member of the epidermal growth factor (EGF) family, strongly upregulated in tumor Intestinal Epithelial cells. EREG acts as a ligand for the EGF receptor (EGFR) and plays a significant role in promoting cell proliferation, survival, and migration, thus contributing to tumor growth and progression in colorectal cancer. GeneCards: EREG
- CD47: Exhibits high expression in tumor Intestinal Epithelial cells. CD47 functions as an immune checkpoint, delivering a "don't eat me" signal to myeloid cells by binding to SIRPα. Its overexpression in cancer cells helps them evade phagocytosis by macrophages, contributing to immune escape and cancer progression. GeneCards: CD47
- SPP1 (Secreted Phosphoprotein 1, Osteopontin): While SPP1 is a secreted protein, its strong upregulation is highly relevant as it interacts with cell surface receptors (e.g., integrins, CD44) to modulate cell adhesion, migration, and immune responses. It is a well-known promoter of tumor growth, metastasis, and angiogenesis. GeneCards: SPP1
- SLC family members (e.g., SLC38A1, SLC52A2, SLC5A6, SLC10A3, SLC38A5): Several solute carrier transporters are also highly expressed in tumor cells. These proteins mediate the transport of various molecules (e.g., amino acids, vitamins, bile salts) across the cell membrane. Their dysregulation can alter cellular metabolism to support rapid proliferation and growth, a hallmark of cancer.
The robust expression of these specific surfaceome and surface-interacting proteins in tumor-origin Intestinal Epithelial cells indicates a profound shift in their cellular identity and function in the cancerous state, involving changes in cell adhesion, growth factor signaling, metabolic reprogramming, and immune evasion.
Clinical or Translational Implications
The identified condition-specific surfaceome markers in Intestinal Epithelial cells have significant clinical and translational implications:
- Diagnostic and Prognostic Biomarkers: Genes like CEACAM1, ADGRE5, EREG, and CD47, due to their distinct upregulation in tumor cells, could serve as highly specific diagnostic markers for colorectal cancer. Their expression levels might also correlate with disease stage, prognosis, or response to therapy, making them valuable prognostic indicators.
- Therapeutic Targets: As these are surfaceome proteins, they represent excellent candidates for targeted therapies. This includes:
- Antibody-Drug Conjugates (ADCs): Antibodies targeting highly expressed surface markers could deliver cytotoxic drugs specifically to tumor cells, minimizing off-target effects.
- CAR T-cell Therapy: Re-engineering T cells to express chimeric antigen receptors (CARs) that recognize these tumor-specific surface proteins could enable precise killing of cancer cells.
- Bispecific Antibodies: Antibodies that simultaneously target a tumor-specific surface marker and an immune cell marker could bridge immune cells to tumor cells for enhanced anti-tumor activity.
- Small Molecule Inhibitors: For receptors like EGFR (activated by EREG), specific kinase inhibitors could block aberrant signaling pathways.
- Experimental Validation: The findings warrant further experimental validation. Techniques such as immunohistochemistry (IHC) on tissue sections, flow cytometry on dissociated tumor cells, and functional assays in 2D/3D cell culture models or patient-derived xenografts (PDX) can confirm protein-level expression and assess the functional impact of targeting these markers on tumor growth and survival. This could pave the way for novel therapeutic strategies against colorectal cancer.
17. Condition-Specific Surfaceome Markers in Macrophages from Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify surfaceome markers that are differentially expressed in macrophages within tumor tissues compared to adjacent normal tissues in the colon. The plot_markers_and_expression_dot tool was used to visualize the mean expression levels and the fraction of cells expressing these markers across individual samples, grouped by condition (tumor vs. adjacent normal). Only surfaceome genes were considered, and up to 50 markers were selected per condition based on differential expression metrics.
Visual Summary
The dot plot effectively visualizes the expression patterns of 31 selected surfaceome markers in macrophages across multiple patient samples. The samples are clearly divided into two major groups: a "tumor" group (upper section, labeled with "tumor") and an "adjacent_normal" group (lower section, separated by a red horizontal line).
- Differential Expression Pattern: A striking pattern of condition-specific gene expression is evident. The majority of the plotted genes show substantially higher mean expression (darker red color) and higher cell prevalence (larger dot size) in the macrophages from tumor samples compared to those from adjacent normal samples. This suggests a significant transcriptional reprogramming of macrophages in the tumor microenvironment (TME).
- Tumor-Enriched Markers: Genes such as PLAUR, FCGR3A, SLC2A3, CD83, SIRPA, CD9, GPNMB, ATP13A3, ICAM1, SCARB2, SLC3A2, HAVCR2, CD84, ITGAX, ADAM10, MMP14, GPR137B, OLR1, TREM1, NRP1, FCGR1A, NECTIN2, ALCAM, and CLEC5A are predominantly and robustly expressed in macrophages from tumor tissues. Many of these markers exhibit strong red colors and large dot sizes in nearly all tumor samples, indicating high expression levels in a large fraction of cells.
- Adjacent Normal-Enriched/General Markers: In contrast, very few markers show clear enrichment in the adjacent normal samples. ABCA1 shows moderate expression in both tumor and adjacent normal macrophages, with some variability. AQP9 also appears broadly expressed across both conditions, suggesting a less condition-specific role within this context.
- Cellular Heterogeneity: Even within the "tumor" group, there is some variability in expression intensity and prevalence across different samples, highlighting inter-patient heterogeneity in the macrophage response to cancer. However, the overarching trend of tumor-specific marker upregulation is clear.
Biological Interpretation
The observed differential expression patterns highlight distinct functional states of macrophages in the tumor microenvironment of colon tissue. Macrophages are highly plastic cells that can adopt various phenotypes, including pro-inflammatory (M1-like) and pro-tumoral (M2-like or Tumor-Associated Macrophages, TAMs) states. The prominent upregulation of specific surfaceome markers in tumor macrophages suggests a shift towards a TAM-like phenotype, which plays crucial roles in cancer progression.
Key tumor-enriched surfaceome markers and their biological implications include:
Immune Checkpoints & Evasion:
- SIRPA (CD172a): This receptor binds to CD47 on tumor cells, delivering a "don't eat me" signal that inhibits phagocytosis by macrophages, thereby enabling immune evasion [1]. Its high expression on TAMs is a significant mechanism for tumor survival.
- HAVCR2 (TIM-3): An immune checkpoint receptor often expressed on exhausted T cells and various myeloid cells including TAMs. Its presence on TAMs can contribute to an immunosuppressive microenvironment, dampening anti-tumor immunity [2].
Tissue Remodeling & Metastasis:
- PLAUR (uPAR): Urokinase Plasminogen Activator Receptor. Elevated PLAUR expression is linked to increased proteolytic activity, promoting extracellular matrix degradation, cell migration, and tumor invasion [3].
- MMP14 (MT1-MMP): A membrane-bound matrix metalloproteinase crucial for degrading the extracellular matrix, facilitating tumor cell invasion, angiogenesis, and metastasis [4]. Its high expression on TAMs indicates their active role in shaping the pro-tumorigenic microenvironment.
Immunosuppression & Pro-Tumoral Signaling:
- GPNMB: Glycoprotein NMB is often associated with the immunosuppressive functions of TAMs, promoting tumor growth and metastasis [5].
- NRP1 (Neuropilin 1): A co-receptor for VEGF and semaphorins, NRP1 plays a key role in angiogenesis and immune regulation. On TAMs, it can facilitate new blood vessel formation and promote an immunosuppressive phenotype, contributing to tumor progression [6].
- OLR1 (LOX-1): Oxidized Low-Density Lipoprotein Receptor 1 is involved in inflammation and oxidative stress, and in cancer, it can promote angiogenesis and tumor progression [7].
- TREM1: Triggering Receptor Expressed on Myeloid cells 1. Amplifies inflammatory responses and can be pro-tumoral by promoting tumor growth and angiogenesis, particularly in the context of chronic inflammation associated with cancer [8].
Macrophage Activation Markers:
- FCGR1A (CD64) and FCGR3A (CD16a): These are Fc gamma receptors indicative of macrophage activation. Their sustained high expression in the TME suggests a highly activated state, which can lead to diverse immune responses depending on the specific context and signaling pathways.
- Other Cell Surface Proteins: CD9, CD83, CD84, ITGAX (CD11c), ADAM10, NECTIN2, ALCAM, CLEC5A also show significant upregulation, participating in various processes like cell adhesion, migration, signaling, and immune modulation, which are critical in the TME.
The relatively lower expression of these markers in adjacent normal tissues suggests that these are not general macrophage activation markers but rather specific adaptations to the tumor environment.
Clinical or Translational Implications
The identification of these condition-specific surfaceome markers in macrophages has significant clinical and translational implications, particularly in the context of colorectal cancer:
- Diagnostic and Prognostic Biomarkers: The highly specific and prevalent expression of markers like SIRPA, GPNMB, MMP14, HAVCR2, and NRP1 on TAMs could serve as valuable biomarkers for identifying and quantifying TAM infiltration in colon cancer biopsies or liquid biopsies. High levels of these markers could be indicative of a more aggressive disease phenotype or predict patient response to therapy.
- Therapeutic Targets for Cancer Immunotherapy: Given that these are surfaceome markers, they represent excellent candidates for targeted therapies.
- SIRPA-CD47 axis blockade is already an active area of cancer immunotherapy research, aiming to unleash macrophage phagocytic activity against tumor cells [9].
- Targeting GPNMB, MMP14, HAVCR2 (TIM-3), NRP1, or TREM1 on TAMs could modulate their pro-tumoral functions (e.g., immunosuppression, angiogenesis, invasion), thereby re-educating the TME and enhancing anti-tumor immunity or reducing metastatic potential.
- Antibody-drug conjugates (ADCs) or bispecific antibodies designed to target these specific surface molecules on TAMs could deliver cytotoxic agents or immune-activating signals directly to tumor-infiltrating macrophages, minimizing off-target effects.
- Patient Stratification and Monitoring: Monitoring the expression levels of these markers, perhaps via immunohistochemistry, flow cytometry, or advanced imaging techniques, could help stratify patients for specific immunotherapies or track the efficacy of treatments that aim to reprogram TAMs.
These findings strongly support further investigation into these specific surfaceome markers as potential targets for therapeutic intervention and as tools for understanding macrophage biology in colorectal cancer.
---
References:
- SIRPA-CD47 signaling: PubMed Search: SIRPA CD47 cancer immunotherapy
- HAVCR2 (TIM-3) in TAMs: PubMed Search: TIM3 TAM immunosuppression
- PLAUR (uPAR) in cancer: PubMed Search: PLAUR cancer invasion
- MMP14 (MT1-MMP) in cancer: PubMed Search: MMP14 cancer metastasis
- GPNMB in TAMs: PubMed Search: GPNMB tumor associated macrophages
- NRP1 in TAMs: PubMed Search: NRP1 TAM angiogenesis
- OLR1 (LOX-1) in cancer: GeneCards: OLR1
- TREM1 in cancer: PubMed Search: TREM1 cancer inflammation
- CD47-SIRPα blockade: PubMed Search: CD47 SIRPa cancer therapy clinical trials
18. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify surfaceome markers that are specifically expressed by Fibroblasts in either "adjacent_normal" or "tumor" conditions within human colon tissue. Surfaceome markers are particularly interesting as they are accessible for cell-cell interactions and potential therapeutic targeting. The plot_markers_and_expression_dot tool was used to visualize the expression patterns and prevalence of these markers across different samples categorized by condition, enabling a direct comparison between normal and tumor-associated fibroblasts.
Visual Summary
The dot plot effectively illustrates the differential expression of fibroblast surfaceome markers between adjacent normal and tumor conditions.
- Adjacent_normal specific markers: A distinct cluster of genes (e.g., PLPP3, SCARA5, GPNMB, ABCA8, PI16, CADM3, CLDN11, PDGFRB, ATP1B3, CDH11, ANTXR1) shows high mean expression (dark red dots) and high prevalence (large dot size) primarily in the adjacent_normal samples (top half of the plot). These genes are largely absent or expressed at very low levels in the tumor samples.
- Tumor specific markers: Conversely, a prominent set of genes (e.g., CD44, ITGAV, PTTG1IP, TGOLN2, TMEM123, ITGA1, PMEPA1, SGCB, HM13, TSPAN3, TMEM30A, NECTIN2, ITGA5, TMEM87A, GLIPR1, PDLIM5, SLC2A3, BMPR2, SLC3A2, IFNGR1, HLA-F, NPTN, FAT1, F2R) exhibits high expression and prevalence almost exclusively in the tumor samples (bottom half of the plot), indicating their upregulation in cancer-associated fibroblasts (CAFs).
- Clarity of separation: The plot clearly delineates two major groups of markers, suggesting a significant phenotypic shift in fibroblasts when transitioning from a normal to a tumor microenvironment.
Biological Interpretation
The differential surfaceome expression highlights the distinct functional roles and activation states of fibroblasts in normal colon tissue versus the tumor microenvironment.
- Normal Fibroblast Markers: Genes like PDGFRB (Platelet-Derived Growth Factor Receptor Beta) and CDH11 (Cadherin-11) are often associated with quiescent or tissue-maintenance fibroblasts, pericytes, or specific stromal subsets. PDGFRB signaling is crucial for wound healing and tissue homeostasis. Its higher expression in adjacent normal fibroblasts suggests a role in maintaining tissue structure and normal stromal function, potentially indicating a less activated state compared to CAFs.
- GeneCards: PDGFRB
- GeneCards: CDH11
- Tumor-Associated Fibroblast (CAF) Markers: The array of highly expressed surfaceome markers in tumor fibroblasts strongly points to their activation into CAFs, which are key drivers of tumor progression in colorectal cancer.
- CD44: A well-known adhesion molecule and receptor for hyaluronan, frequently associated with cancer stemness, cell migration, and metastasis. Its upregulation in CAFs can contribute to ECM remodeling and creating a pro-tumorigenic niche.
- GeneCards: CD44
- Integrins (ITGAV, ITGA1, ITGA5): These alpha integrin subunits form heterodimers with beta integrins and are critical for cell-extracellular matrix (ECM) interactions. Their upregulation in CAFs indicates enhanced adhesion, migration, and signaling with the ECM, facilitating matrix stiffening and remodeling that promotes tumor invasion and metastasis.
- GeneCards: ITGAV
- GeneCards: ITGA1
- GeneCards: ITGA5
- PMEPA1: This protein regulates TGF-beta signaling, a major pathway for CAF activation and fibrotic responses. Its overexpression in tumor fibroblasts suggests an active role in perpetuating TGF-beta-mediated stromal activation.
- GeneCards: PMEPA1
- SLC2A3 (GLUT3) and SLC3A2 (CD98hc): These are glucose and amino acid transporters, respectively. Their upregulation points to altered metabolism in CAFs, possibly indicative of increased nutrient uptake to support their highly active state, proliferation, and synthesis of ECM components, a hallmark of cancer metabolism.
- GeneCards: SLC2A3
- GeneCards: SLC3A2
- BMPR2: As a receptor for Bone Morphogenetic Proteins, part of the TGF-beta superfamily, its expression suggests active signaling through these pathways, further contributing to CAF activation and ECM changes.
- GeneCards: BMPR2
- HLA-F and IFNGR1: The expression of these immune-related surface molecules on CAFs suggests active crosstalk with immune cells within the tumor microenvironment. HLA-F is a non-classical MHC class I molecule that can modulate immune responses, while IFNGR1 (Interferon Gamma Receptor 1) indicates responsiveness to IFN-gamma, potentially influencing CAF phenotype in an inflammatory TME.
- GeneCards: HLA-F
- GeneCards: IFNGR1
- FAT1: While complex in its role, FAT atypical cadherin 1 is involved in cell-cell adhesion and signaling, and its dysregulation can impact cell proliferation and differentiation, contributing to the CAF phenotype.
- GeneCards: FAT1
The observed markers reflect the well-established role of CAFs in promoting chronic inflammation, immune evasion, angiogenesis, and metastatic dissemination in colorectal cancer.
Clinical or Translational Implications
The identification of condition-specific surfaceome markers for fibroblasts holds significant clinical and translational potential:
- Biomarker Discovery: The distinct set of highly expressed surface proteins in tumor-associated fibroblasts could serve as specific diagnostic or prognostic biomarkers for colorectal cancer, potentially detectable through tissue biopsies or liquid biopsies (e.g., circulating tumor cells or extracellular vesicles derived from CAFs).
- Therapeutic Targets: Surface molecules are highly attractive for therapeutic intervention due to their accessibility. Genes like CD44, ITGAV/ITGA1/ITGA5 (integrins), PMEPA1, SLC2A3, and SLC3A2 represent compelling candidates for targeted therapies aimed at modulating CAF function. Strategies could include:
- Antibody-drug conjugates (ADCs): Delivering cytotoxic agents specifically to CAFs.
- CAR-T cell therapy: Targeting CAFs to remodel the tumor microenvironment and enhance anti-tumor immunity.
- Small molecule inhibitors: Blocking crucial CAF signaling pathways or metabolic activities.
- Modulating integrin activity could disrupt CAF-ECM interactions, reducing tumor invasion and metastasis.
- Targeting altered glucose and amino acid transporters (SLC2A3, SLC3A2) could starve CAFs and impair their pro-tumorigenic functions.
- Drug Resistance Modulation: CAFs are known mediators of therapeutic resistance. Targeting these specific surface markers could offer strategies to overcome resistance to conventional chemotherapy or immunotherapy by re-sensitizing tumors to treatment.
- Experimental Validation: The identified markers provide a strong basis for further experimental validation using techniques such as immunohistochemistry, flow cytometry, or functional assays in 3D culture models or in vivo studies to confirm their utility as specific fibroblast markers and evaluate their therapeutic potential.
19. CD4 T cell Condition-Specific Surfaceome Markers in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
이 분석은 단일 세포 RNA 시퀀싱 데이터를 활용하여 대장 조직 내 CD4 T 세포에서 종양(tumor)과 인접 정상(adjacent_normal) 조직 간의 조건별 표면 단백질(surfaceome) 마커를 식별한 결과입니다. 표면 단백질에 초점을 맞춤으로써, 잠재적인 진단 바이오마커 또는 치료 표적을 발굴하는 데 유리합니다. 마커의 발현 수준(점의 색상 강도)과 해당 마커를 발현하는 세포의 비율(점의 크기)이 시각적으로 표현되어 있습니다.
Visual Summary
도트 플롯은 CD4 T 세포의 다양한 클러스터(Y축)에 걸쳐 인접 정상 및 종양 조건(X축 상단)에서 특정 유전자(X축 하단)의 발현 패턴을 보여줍니다.
- 인접 정상 조직 특이적 마커: CCR7, IL2RG, TNFRSF18 (GITR), TNFRSF4 (OX40), BST2 (CD317)와 같은 유전자들은 주로 상단 부분의 클러스터(예: C113-C150)에서 인접 정상 조건에서 더 높은 발현 수준(더 진한 붉은색)과 더 넓은 세포 분율(더 큰 점)을 보입니다.
- 종양 조직 특이적 마커: CTLA4, TIGIT, CD6, ICOS, ENTPD1 (CD39), HLA-DPA1, HLA-DPB1, HLA-DRB1, HLA-DRA (MHC Class II), IL2RB, ITGB1 (CD29)와 같은 유전자들은 주로 중간 및 하단 부분의 클러스터(예: C159, C169, C194 등)에서 종양 조건에서 매우 높은 발현 수준과 높은 세포 분율을 나타냅니다. 특히 CTLA4와 TIGIT은 종양 조건의 여러 클러스터에서 강하게 발현됩니다.
- 범용 마커: CD4는 모든 클러스터에서 발현되며, 이는 분석 대상 세포가 CD4 T 세포임을 확인합니다. CD74 및 LMAN2와 같은 유전자는 두 조건에서 비교적 넓게 발현되지만, 조건 간 차이는 덜 뚜렷합니다.
- 클러스터 분포: 플롯의 오른쪽에 있는 막대 차트는 각 클러스터의 세포 수가 조건(인접 정상 vs. 종양)에 따라 어떻게 분포하는지 보여줍니다. 예를 들어, CCR7이 풍부한 클러스터는 인접 정상 조직에서 세포 수가 더 많고, CTLA4와 TIGIT이 풍부한 클러스터는 종양 조직에서 더 많은 세포를 가집니다. 이는 특정 CD4 T 세포 하위 유형이 조건에 따라 달라진다는 것을 시사합니다.
Biological Interpretation
이 분석 결과는 대장 조직 미세환경에서 CD4 T 세포의 기능적 상태 및 아형 분포가 종양 발생에 따라 현저하게 변화함을 강력하게 시사합니다.
- 인접 정상 조직의 CD4 T 세포:
- CCR7: 림프절로의 순환 및 귀환에 중요한 역할을 하는 케모카인 수용체로, 나이브(naive) 또는 중앙 기억 T 세포(central memory T cell)의 특징적인 마커입니다 PubMed search: CCR7 T cell function. 인접 정상 조직에서 높은 발현은 이러한 T 세포 아형이 정상적인 면역 감시 또는 기억 기능에 관여함을 나타냅니다.
- IL2RG: 여러 사이토카인 수용체의 공통 감마 사슬(common gamma chain)로, T 세포 발달 및 기능에 필수적입니다 GeneCards: IL2RG. 인접 정상 조직의 T 세포가 사이토카인 신호에 잘 반응하고 있음을 시사합니다.
- TNFRSF18 (GITR) 및 TNFRSF4 (OX40): 이들은 공동 자극 수용체로, T 세포 활성화에 중요합니다 UniProt: TNFRSF18, UniProt: TNFRSF4. 인접 정상 조직에서도 특정 T 세포 아형이 어느 정도 활성화 상태에 있거나, 조절 T 세포(Treg)의 표현형일 수 있습니다.
- 종양 미세환경의 CD4 T 세포 (TILs):
면역 관문 분자 (Immune Checkpoints):
- CTLA4: T 세포 활성화를 억제하는 고전적인 면역 관문 분자로, 종양 미세환경에서 T 세포의 기능 부전(dysfunction) 또는 고갈(exhaustion)을 나타내는 주요 마커입니다 GeneCards: CTLA4.
- TIGIT: 또 다른 억제성 면역 관문 분자로, CTLA4와 함께 T 세포 고갈의 지표로 자주 나타납니다 PubMed search: TIGIT cancer.
- ENTPD1 (CD39): 세포 외 ATP/ADP를 면역 억제성 아데노신(adenosine)으로 전환하는 효소로, 종양 미세환경에서 면역 억제를 촉진하고 종종 고갈된 T 세포 및 조절 T 세포에서 발현됩니다 PubMed search: CD39 T cell exhaustion.
활성화 및 MHC Class II 관련 분자:
- ICOS (CD278): T 세포 활성화 및 분화에 중요한 공동 자극 수용체로, 특히 Th17 및 Tfh 세포의 특징입니다 UniProt: ICOS. 종양 내 CD4 T 세포의 활성화 상태를 반영합니다.
- HLA-DPA1, HLA-DPB1, HLA-DRB1, HLA-DRA (MHC Class II): MHC Class II 분자는 주로 항원 제시 세포(APC)에서 발현되지만, 활성화된 T 세포에서도 상향 조절될 수 있으며, 이는 T 세포의 활성화 또는 특정 아형(예: 일부 조절 T 세포)에서의 발현을 나타낼 수 있습니다 PubMed search: MHC Class II T cell activation.
- IL2RB (CD122): IL-2 수용체 베타 사슬로, T 세포 활성화 및 증식에 필수적인 IL-2 신호 전달에 관여합니다 GeneCards: IL2RB.
- ITGB1 (CD29): 인테그린 베타-1은 세포 접착 및 이동에 관여하며, 활성화된 T 세포에서 발현이 증가하는 경우가 많습니다 UniProt: ITGB1.
전반적으로, 종양 미세환경 내 CD4 T 세포는 면역 억제성 면역 관문 분자(CTLA4, TIGIT, ENTPD1)와 활성화 및 기능 관련 분자(ICOS, MHC Class II, IL2RB, ITGB1)를 동시 발현하는 경향을 보입니다. 이는 종양 침윤 CD4 T 세포가 활성화되었지만, 동시에 면역 억제 경로에 의해 조절되거나 기능적으로 고갈되었을 가능성을 시사합니다.
Clinical or Translational Implications
이 분석에서 식별된 조건 특이적 표면 마커는 대장암 진단, 예후 및 치료에 중요한 임상적 의미를 가질 수 있습니다.
- 바이오마커 개발:
- CTLA4, TIGIT, ENTPD1 (CD39), ICOS, HLA-DR genes과 같은 종양 특이적 마커들은 종양 미세환경 내 CD4 T 세포의 활성화 및 면역 억제 상태를 평가하기 위한 잠재적인 바이오마커로 활용될 수 있습니다. 이러한 마커들은 유세포 분석(flow cytometry)이나 면역조직화학(immunohistochemistry)을 통해 종양 침윤 림프구(TILs)의 특성을 파악하는 데 사용될 수 있습니다.
- 특히 CTLA4와 TIGIT은 현재 면역 관문 억제제(immune checkpoint inhibitors)의 표적으로 사용되고 있어, 이러한 마커들의 발현 패턴은 특정 환자 집단에서 면역 치료 반응 예측에 기여할 수 있습니다.
- 치료 표적 발굴:
- 종양 특이적으로 상향 조절되는 면역 관문 분자(예: CTLA4, TIGIT, ENTPD1)는 종양 면역 반응을 강화하기 위한 새로운 치료 전략 개발의 표적이 될 수 있습니다. 이들을 표적으로 하는 항체 치료제는 T 세포의 고갈을 역전시키고 항종양 면역을 증진시킬 수 있습니다.
- ICOS와 같은 공동 자극 분자도 T 세포 기능을 활성화하기 위한 잠재적 표적으로 고려될 수 있습니다.
- 질병 이해 및 환자 계층화:
- 정상과 종양 조직에서 CD4 T 세포의 표면 마커 프로파일 차이를 이해하는 것은 대장암 진행 중 T 세포 면역 반응의 변화를 심층적으로 이해하는 데 중요합니다.
- 환자 간 CD4 T 세포 아형 및 이들의 마커 발현 패턴의 이질성을 분석하여, 특정 CD4 T 세포 표현형과 임상 결과 사이의 연관성을 탐색하고 환자 맞춤형 치료 전략을 개발하는 데 활용될 수 있습니다.
20. Dysregulation of Cell Cycle Genes in Intestinal Epithelial Cells of Colon Tumors
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the differential expression of genes involved in the Cell Cycle pathway within Intestinal Epithelial cells, comparing tumor tissue to adjacent normal tissue from colon samples. The aim is to identify specific cell cycle regulators that exhibit statistically significant expression changes in the tumor context, providing insights into the proliferative dynamics of colorectal cancer.
Visual Summary
The provided box plots display the gene expression levels (sample mean) for numerous cell cycle-related genes across Intestinal Epithelial cells, stratified by 'tumor' and 'adjacent_normal' conditions.
- Consistent Upregulation in Tumor: A striking and highly consistent pattern is observed across nearly all plotted genes. Intestinal Epithelial cells from 'tumor' samples (blue boxes) show significantly higher expression levels compared to those from 'adjacent_normal' samples (orange boxes).
- Statistical Significance: For almost every gene depicted, the difference in expression between tumor and adjacent normal conditions is statistically significant, with p-values predominantly at p ≤ 0.05, p ≤ 0.01, or even p ≤ 0.001. This indicates a robust and widespread upregulation of these cell cycle genes in the tumor microenvironment.
- Distribution: While expression levels in tumor cells are generally higher, the spread of data points (individual black dots representing samples) within each boxplot indicates biological variability among samples, though the central tendency clearly favors higher expression in tumor tissue.
Biological Interpretation
The pervasive and significant upregulation of a broad spectrum of cell cycle genes in Intestinal Epithelial cells from colon tumors strongly points towards an enhanced proliferative state as a hallmark of the tumor cells. This aligns with the fundamental understanding of cancer, where uncontrolled cell division is a key characteristic.
- Core Cell Cycle Machinery Activation: Genes encoding components of the Anaphase-Promoting Complex/Cyclosome (APC/C) such as ANAPC1, ANAPC5, ANAPC7, ANAPC10, CDC20, CDC23, CDC26, CDC27, FZR1 are consistently elevated. The APC/C is crucial for driving cells through mitosis. Similarly, key cyclins (CCNB1, CCNB2, CCND1, CCND3, CCNH) and cyclin-dependent kinases (CDK1, CDK4, CDK6, CDK7) – the central regulators of cell cycle progression – are also significantly upregulated. This collective activation signifies an aggressive and accelerated cell division program in tumor-derived Intestinal Epithelial cells. [GeneCards: CCNB1]
- DNA Replication and Chromatin Management: Genes involved in DNA replication initiation and elongation, such as Minichromosome Maintenance proteins (MCM3, MCM4, MCM5, MCM6, MCM7), Origin Recognition Complex components (ORC2, ORC3, ORC4, ORC6), DBF4, CDC45, and PCNA, show elevated expression. These are essential for the accurate duplication of the genome during the S-phase, and their upregulation reflects increased DNA synthesis activity in rapidly dividing cancer cells. [GeneCards: MCM2] Additionally, components of the cohesin complex (RAD21, SMC1A, SMC3, STAG1, STAG2), which are critical for sister chromatid cohesion during mitosis, are also upregulated, indicating active cell division.
- Checkpoint and Stress Response Genes: While many genes driving progression are upregulated, some genes involved in cell cycle checkpoints and DNA damage response, such as ATM, CHEK1, TP53, WEE1, BUB3, MAD2L1, and MAD2L2, also show increased expression. This can be interpreted in several ways:
- Compensation for Stress: Rapid and unregulated proliferation often leads to replication stress and genomic instability. Upregulation of checkpoint genes (e.g., CHEK1, WEE1) might represent an attempt by cancer cells to manage this stress and survive despite the high proliferative burden. [PubMed: CHEK1 cancer replication stress]
- Dysfunctional Checkpoints: Alternatively, despite their upregulation, these checkpoints might be overridden or become less effective in preventing abnormal cell division in cancer. For instance, TP53 is a critical tumor suppressor, and its upregulation could reflect a cellular response to oncogenic stress, though its function is often compromised in cancer.
- Transcriptional Control of Proliferation: Transcription factors like E2F3, E2F4, TFDP1, and TFDP2, which control the expression of numerous genes involved in cell cycle progression and DNA synthesis, are also upregulated, further underscoring the coordinated activation of the proliferative program. [GeneCards: E2F1]
- Context of Tumor Origin Cell Type: Given that Intestinal Epithelial cells are the stated tumor origin cell type, these findings provide direct evidence of intrinsic cellular changes driving tumor growth, rather than merely reactive changes from the surrounding microenvironment. The contrast with adjacent normal intestinal epithelial cells highlights the significant pathological shift in cellular behavior. The context of ploidy_dec (Aneuploid/Diploid) in the AnnData is highly relevant here, as sustained cell cycle dysregulation, as evidenced by these gene expression changes, often leads to aneuploidy and genomic instability, common features of colorectal cancer cells.
Clinical or Translational Implications
- Biomarker Potential: The consistent and pronounced upregulation of a wide array of cell cycle genes in tumor-derived Intestinal Epithelial cells suggests their potential as robust diagnostic or prognostic biomarkers for colorectal cancer. High expression of these genes could indicate the presence of tumor cells, disease aggressiveness, or risk of recurrence.
- Therapeutic Targets: The cell cycle pathway is a well-established and attractive target for anti-cancer therapies. The observed broad activation of this pathway in Intestinal Epithelial cells in colon tumors indicates a strong dependence of these cancer cells on active proliferation.
- Specific upregulated genes like CDK1, CDK4, CDK6, CHEK1, and WEE1 are targets for various cell cycle inhibitors, some of which are already approved or in clinical trials for other cancers. For example, CDK4/6 inhibitors are widely used in breast cancer treatment. [PubMed: CDK4/6 inhibitors cancer] The data suggest that similar strategies could be explored for colorectal cancer, potentially offering a therapeutic avenue by disrupting the tumor's hyperactive cell cycle. [PubMed: cell cycle inhibitors colorectal cancer]
- Targeting genes involved in DNA replication (MCM, ORC family) or mitotic checkpoints (BUB, MAD family) could also represent valid strategies to induce cell death or senescence in highly proliferative tumor cells.
- Disease Understanding: These findings deepen our understanding of the molecular mechanisms driving colorectal cancer, emphasizing the critical role of cell cycle dysregulation in the tumor's primary cellular component. This knowledge can guide the development of more effective and targeted therapies.
21. 장 상피세포(Intestinal Epithelial cell)의 유전자 온톨로지(GSA) 분석 결과
[Analysis Visualization Results]...
Analysis Overview
본 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 활용하여 장 상피세포(Intestinal Epithelial cell)에서 유전자 온톨로지(Gene Ontology, GO) 분석(GSA)을 수행한 결과입니다. 이 분석은 특정 생물학적 상태에서 장 상피세포의 기능적 변화를 탐색하는 데 중점을 두었으며, 두 가지 주요 비교 그룹에 대한 결과를 제공합니다.
- Diploid_vs_others: 핵형(ploidy)이 이배체(Diploid)인 장 상피세포와 그 외의 세포(대부분 이수체(Aneuploid) 상피세포로 추정됨)를 비교하여 이배체 상피세포에서 상향 조절되는 GO 용어를 확인했습니다.
- tumor_vs_others: 대장암 종양(tumor) 조직 내 장 상피세포와 인접 정상(adjacent_normal) 조직 내 장 상피세포를 비교하여 종양 환경의 상피세포에서 상향 조절되는 GO 용어를 분석했습니다.
결과는 통계적 유의성(-log(p-val) 및 -log(q-val))을 기준으로 정렬된 막대 그래프로 시각화되어 있습니다.
Visual Summary
제공된 두 개의 막대 그래프는 장 상피세포에서 특정 조건과 비교하여 상향 조절된 유전자 온톨로지(GO) 용어들의 통계적 유의성(p-value 및 q-value의 -log 값)을 보여줍니다. 각 그래프는 왼쪽 패널에 -log(p-val) 값을, 오른쪽 패널에 -log(q-val) 값을 표시하며, 두 값 모두 높을수록 해당 용어가 통계적으로 더 유의미하게 상향 조절되었음을 의미합니다.
- "GSA_up for Intestinal Epithelial cell: Diploid_vs_others" 그래프: 이배체 장 상피세포에서 상향 조절된 GO 용어들을 보여줍니다. 최상위 용어들은 주로 Epstein-Barr virus infection, Intestinal immune network for IgA production, Antigen processing and presentation 등 면역 반응과 관련된 용어들이며, p-value는 약 1e-7 수준(p-val의 -log 값 7)의 유의성을 보입니다. 이는 이배체 상피세포가 특정 면역 관련 기능을 가질 수 있음을 시사합니다.
- "GSA_up for Intestinal Epithelial cell: tumor_vs_others" 그래프: 종양 조직 내 장 상피세포에서 상향 조절된 GO 용어들을 보여줍니다. 이 그래프에서는 Endocytosis, Protein processing in endoplasmic reticulum, Ubiquitin mediated proteolysis, Cell cycle 등과 같이 세포의 기본적인 기능 및 암과 관련된 핵심 경로들이 훨씬 더 높은 통계적 유의성(p-val의 -log 값 약 20 이상)으로 상향 조절된 것으로 나타납니다. 전반적으로 종양 상피세포의 변화가 이배체 상피세포의 변화보다 훨씬 더 광범위하고 통계적으로 강력하게 나타남을 알 수 있습니다.
Biological Interpretation
1. Diploid 장 상피세포의 생물학적 특성 (vs. Other 상피세포)
이배체(Diploid) 장 상피세포에서 상향 조절된 GO 용어들은 주로 면역 및 염증 반응, 그리고 정상적인 세포 기능과 관련이 깊습니다.
- 면역 및 염증 반응: "Epstein-Barr virus infection", "Intestinal immune network for IgA production", "Allograft rejection", "Graft-versus-host disease", "Antigen processing and presentation" 등의 용어들은 장 상피세포가 단순한 장벽 기능 외에 다양한 면역 반응에 적극적으로 관여하고 있음을 시사합니다. 특히 IgA 생산을 위한 장 면역 네트워크는 장 점막의 핵심적인 방어 기전입니다. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205020/ 이는 이배체 상피세포가 이수체(Aneuploid) 상피세포에 비해 상대적으로 덜 변형되고 면역 조절 기능을 유지하고 있을 가능성을 나타냅니다.
- 대사 및 흡수: "Mineral absorption"과 같은 용어는 장 상피세포의 기본적인 흡수 기능을 반영합니다.
이러한 결과는 이배체 장 상피세포가 핵형 불안정성을 특징으로 하는 암세포에 비해 더욱 정상적인 생리적 기능, 특히 면역 항상성 유지에 중요한 역할을 할 수 있음을 시사합니다.
2. 종양 내 장 상피세포의 생물학적 특성 (vs. Adjacent normal 상피세포)
종양(tumor) 조직 내 장 상피세포에서 상향 조절된 GO 용어들은 대장암 세포의 특징적인 높은 증식률, 단백질 대사 이상, 세포 스트레스 반응, 그리고 세포 생존 메커니즘과 밀접하게 연관되어 있습니다.
- 세포 성장 및 분열: "Cell cycle"이 매우 강하게 상향 조절된 것은 종양 상피세포의 통제되지 않는 증식을 직접적으로 반영합니다. 이는 암의 가장 근본적인 특징입니다.
- 단백질 항상성 및 대사: "Endocytosis", "Protein processing in endoplasmic reticulum", "Ubiquitin mediated proteolysis", "Ribosome", "RNA transport" 등의 용어들은 종양 세포가 빠른 성장을 위해 단백질 합성 및 분해, RNA 대사 등 전반적인 세포 내 대사 활동을 비정상적으로 높이고 있음을 보여줍니다. 특히 ER 스트레스 및 유비퀴틴-프로테아좀 시스템의 활성화는 암세포의 높은 단백질 부하를 처리하기 위한 중요한 적응 기전입니다.
- 세포 스트레스 및 사멸 조절: "Autophagy", "Cellular senescence"는 암세포가 스트레스에 대응하고 생존을 유지하기 위해 활성화하는 복합적인 과정들입니다. 자가포식(Autophagy)은 암의 진행 단계에 따라 종양 억제 또는 종양 촉진 역할을 할 수 있습니다. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945653/
- 핵심 암 관련 신호 전달 경로: "mTOR signaling pathway", "p53 signaling pathway", "Insulin signaling pathway", "MAPK signaling pathway", "FoxO signaling pathway" 등은 암 발병 및 진행에 중요한 역할을 하는 핵심적인 세포 성장 및 생존 신호 전달 경로들입니다. 특히 mTOR 경로는 세포 성장, 증식, 대사를 조절하며 대장암을 포함한 다양한 암에서 활성화되어 있습니다. https://pubmed.ncbi.nlm.nih.gov/22906889/
- 발암 관련 용어: "Viral carcinogenesis"는 암세포의 전반적인 발암 기전 활성화 및 바이러스 감염을 통한 암 발생 가능성을 반영할 수 있습니다.
- 신경 퇴행성 질환 관련 용어: "Amyotrophic lateral sclerosis", "Huntington disease", "Alzheimer disease", "Parkinson disease", "Pathways of neurodegeneration" 등의 용어는 암세포에서 단백질 응집, 산화 스트레스, 미토콘드리아 기능 이상 등 신경 퇴행성 질환과 공유하는 세포 스트레스 및 손상 반응 기전이 활성화되어 있음을 시사합니다. 이는 암세포의 병리학적 변화의 한 측면으로 해석될 수 있습니다.
이러한 결과는 종양 내 장 상피세포가 정상 상피세포와 비교하여 증식, 대사, 단백질 처리, 스트레스 반응 등 광범위한 세포 생물학적 과정에서 현저한 변화를 겪고 있으며, 이는 대장암 세포의 특징적인 악성 표현형을 형성하는 데 기여함을 명확히 보여줍니다.
Clinical or Translational Implications
- 암 진단 및 예후 마커 발굴: 종양 상피세포에서 강력하게 상향 조절되는 "Cell cycle" 관련 유전자, "mTOR signaling pathway" 구성 요소, "Ubiquitin mediated proteolysis" 관련 유전자 등은 대장암의 진행 정도나 공격성을 평가하는 바이오마커로 활용될 수 있습니다.
- 잠재적 치료 표적 발굴: mTOR 신호 전달 경로와 같은 핵심 암 관련 경로의 활성화는 해당 경로를 표적으로 하는 치료제(예: mTOR 억제제)의 임상적 유용성을 시사합니다. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754117/ 또한, 단백질 항상성(proteostasis) 관련 경로(ER stress, ubiquitin-proteasome system)의 이상 활성화는 이러한 시스템을 조절하는 약물을 통한 암 치료 전략 개발 가능성을 제시합니다.
- 면역 치료와의 연관성: Diploid 상피세포에서 면역 관련 경로(IgA 생산 네트워크, 항원 처리 및 제시)가 활성화되어 있다는 점은 종양 미세 환경 내 정상 또는 덜 변형된 상피세포가 면역 반응에 어떤 역할을 하는지 추가 연구할 필요성을 시사합니다. 이는 면역 체크포인트 억제제와 같은 면역 요법의 반응을 예측하거나 개선하는 데 중요한 단서를 제공할 수 있습니다.
- 세포 스트레스 및 대사 조절: 종양 상피세포의 대사 및 스트레스 반응 경로(Autophagy, Endocytosis 등)의 변화는 대장암 세포의 생존 전략을 이해하고, 이들 경로를 조절하여 암세포의 취약점을 공략하는 새로운 치료 접근법을 개발하는 데 기여할 수 있습니다.
22. Gene Set Enrichment Analysis Reveals Condition-Specific Pathway Alterations Across Colon Cell Types
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Set Enrichment Analysis (GSEA) results for various major cell types found in the colon tissue, comparing gene expression profiles under different conditions. The conditions include 'adjacent_normal_vs_others' (cells from adjacent normal tissue compared to all other cells), 'tumor_vs_others' (cells from tumor tissue compared to all other cells), and for Intestinal Epithelial cells, 'Diploid_vs_others' and 'Aneuploid_vs_others' (comparing cells based on their ploidy status). The results are visualized as a dot plot, where dot color indicates the Normalized Enrichment Score (NES) (red for positive enrichment, blue for negative enrichment) and dot size reflects the significance of enrichment (-log10(p-value)).
Visual Summary
The dot plot reveals distinct patterns of pathway enrichment and suppression across different cell types and conditions:
- Intestinal Epithelial Cells (Tumor & Aneuploid): Show a strong and consistent positive enrichment (red, large dots) for pathways associated with cell proliferation and aggressive tumor characteristics. These include "Cell cycle", "DNA replication", "Mismatch repair", "Ribosome biogenesis in eukaryotes", "Splicing", "Proteasome", "Oxidative phosphorylation", and key oncogenic signaling pathways like "Wnt signaling pathway" and "Hedgehog signaling pathway". Notably, the 'Aneuploid_vs_others' comparison for Intestinal Epithelial cells mirrors the 'tumor_vs_others' enrichment profile, suggesting aneuploidy is a strong indicator of actively proliferating and transformed epithelial cells.
Immune Cells (Macrophages, T cells, Plasma cells, B cells)
- Macrophages (tumor_vs_others): Display significant positive enrichment for inflammatory and immune signaling pathways such as "Cytosolic DNA-sensing pathway", "NOD-like receptor signaling pathway", "Inflammatory bowel disease", "IL-17 signaling pathway", and "TNF signaling pathway". "Oxidative phosphorylation" is also highly enriched.
- T cells (CD4+ and CD8+, tumor_vs_others): Show enrichment for inflammatory pathways (e.g., "IL-17 signaling pathway", "Th17 cell differentiation") and "Cytosolic DNA-sensing pathway". "Antigen processing and presentation" is also enriched in CD4+ T cells in the tumor.
- Plasma cells (tumor_vs_others): Exhibit enrichment in "Antigen processing and presentation", "Cytosolic DNA-sensing pathway", "Inflammatory bowel disease", and "IL-17 signaling pathway".
- B cells (tumor_vs_others): Show positive enrichment for "Cytosolic DNA-sensing pathway" and "Inflammatory bowel disease".
Stromal Cells (Fibroblasts, Smooth Muscle cells)
- Fibroblasts (tumor_vs_others): Demonstrate strong enrichment for inflammatory pathways ("Inflammatory bowel disease", "IL-17 signaling pathway", "TNF signaling pathway", "Cytosolic DNA-sensing pathway") and "Wnt signaling pathway".
- Smooth Muscle cells (tumor_vs_others): Also show enrichment for "Inflammatory bowel disease" and "IL-17 signaling pathway".
- Endothelial Cells (tumor_vs_others): Exhibit positive enrichment for "Endocytosis", "FoxO signaling pathway", and "Oxidative phosphorylation". There's also a negative enrichment (blue) for "TNF signaling pathway" and "Hepatocellular carcinoma" related pathways.
- Adjacent Normal Tissue: In contrast, cells from adjacent normal tissue (e.g., Intestinal Epithelial cell, B cell, Endothelial cell: adjacent_normal_vs_others) generally show a suppression (blue) of proliferative pathways and, in some cases, distinct enrichment for pathways not prominent in tumor cells (e.g., "Autophagy" in adjacent normal Intestinal Epithelial cells).
Biological Interpretation
The GSEA results provide clear insights into the functional landscape of colon tissue in the context of cancer:
- Tumor Cell Proliferation and Metabolic Reprogramming: The dominant signature in 'tumor_vs_others' and 'Aneuploid_vs_others' Intestinal Epithelial cells is the upregulation of pathways critical for cell growth, division, and energy production (Cell cycle, DNA replication, Ribosome biogenesis, Proteasome, Oxidative phosphorylation). This highlights the high proliferative activity and altered metabolism characteristic of cancer cells, which shift their energy production to support rapid division [1, 2]. The enrichment of "Mismatch repair" in these cells might indicate ongoing genomic instability or compensatory repair mechanisms.
- Oncogenic Signaling: Activation of "Wnt signaling pathway" and "Hedgehog signaling pathway" in tumor/aneuploid epithelial cells and fibroblasts underscores their crucial roles in colon cancer development, progression, and shaping the tumor microenvironment [3, 4]. Dysregulation of Wnt signaling is a well-established driver in colorectal cancer.
- Inflammatory Tumor Microenvironment: Immune cells (Macrophages, T cells, Plasma cells, B cells) and stromal cells (Fibroblasts, Smooth muscle cells) within the tumor microenvironment exhibit a pro-inflammatory profile. Upregulation of "IL-17 signaling pathway," "TNF signaling pathway," and "Inflammatory bowel disease" related pathways indicates a chronic inflammatory state that can promote tumor growth, immune evasion, and metastasis [5, 6]. The activation of "Cytosolic DNA-sensing pathway" (cGAS-STING pathway) in these cells may be a response to tumor-derived DNA, triggering innate immune responses, which can be either anti-tumor or pro-tumor depending on context [7].
- Cancer-Associated Fibroblasts (CAFs): The enrichment of inflammatory and Wnt signaling pathways in fibroblasts in the tumor suggests their transformation into CAFs, which are known to play a critical role in ECM remodeling, immune suppression, and supporting tumor progression in colorectal cancer [4].
- Endothelial Cell Activity: Upregulation of "Endocytosis" and "Oxidative phosphorylation" in tumor endothelial cells may reflect increased cellular activity associated with angiogenesis and metabolic demands within the growing tumor.
Clinical or Translational Implications
These GSEA findings have several clinical and translational implications for colon cancer:
- Therapeutic Targets: The strong activation of "Wnt signaling pathway" in epithelial tumor cells and fibroblasts suggests that Wnt pathway inhibitors could be effective therapeutic agents, potentially targeting both cancer cells and supportive stromal cells. Pathways related to cell proliferation (Cell cycle, DNA replication) and proteasome activity also represent classic targets for chemotherapy and targeted therapies.
- Metabolic Vulnerabilities: The consistent enrichment of "Oxidative phosphorylation" in tumor epithelial cells, macrophages, and endothelial cells suggests metabolic reprogramming, which could be exploited by drugs that target specific metabolic pathways to starve cancer cells or impair the supportive tumor microenvironment.
- Modulating Inflammation: The prominent inflammatory signature in immune and stromal cells within the tumor microenvironment, particularly through "IL-17 signaling pathway" and "TNF signaling pathway", indicates that anti-inflammatory strategies or immunomodulatory therapies could be beneficial. Targeting these pathways might reduce pro-tumorigenic inflammation and enhance anti-tumor immunity.
- Biomarkers: The identified enriched pathways could serve as potential biomarkers for disease progression, response to therapy, or patient stratification. For instance, high activity of Wnt signaling or inflammatory pathways might indicate more aggressive disease or responsiveness to specific inhibitors.
- Ploidy as a Prognostic Indicator: The close resemblance of pathway enrichment between 'Aneuploid_vs_others' and 'tumor_vs_others' for Intestinal Epithelial cells reinforces aneuploidy as a key characteristic of transformed cells and potentially a prognostic marker.
References
- Oxidative phosphorylation in cancer metabolism:
PubMed search: "oxidative phosphorylation cancer metabolism"
- Cell cycle in cancer:
- Wnt signaling pathway in colorectal cancer:
PubMed search: "Wnt signaling colorectal cancer"
- Hedgehog signaling pathway in cancer:
PubMed search: "Hedgehog signaling pathway cancer"
- IL-17 signaling in tumor microenvironment:
PubMed search: "IL-17 signaling tumor microenvironment"
- TNF signaling in tumor microenvironment:
PubMed search: "TNF signaling tumor microenvironment"
- cGAS-STING pathway in cancer:
PubMed search: "cGAS-STING pathway cancer"
23. Discussion
This comprehensive single-cell analysis of human colon tissue provides a multi-faceted view of colorectal cancer (CRC), integrating cellular heterogeneity, genetic alterations, cell-cell interactions, and pathway dysregulation. A central finding is the robust identification of malignant Intestinal Epithelial cells through their distinct clustering, predominant presence in tumor samples, and, most critically, their widespread aneuploidy. The observation of aneuploid epithelial cells in some 'adjacent normal' samples is particularly noteworthy, suggesting a field cancerization effect or early oncogenic events prior to overt histological malignancy, which has significant implications for surveillance and risk assessment.
The tumor microenvironment (TME) undergoes profound remodeling. Macrophage populations show a complex shift with an increase in M1-like macrophages but a decrease in M2B, indicating a nuanced rather than a simple pro-tumor M2 polarization. T cell subsets demonstrate a clear increase in immunosuppressive regulatory T cells (Tregs) and regulatory innate lymphoid cells (ILCregs), alongside a trend for increased Th17 cells and a decrease in ILC2s. This points to a highly immunosuppressive TME that dampens anti-tumor immunity despite the presence of cytotoxic T cells. Fibroblasts also undergo significant transformation, adopting a cancer-associated fibroblast (CAF) phenotype with altered surface markers (e.g., CD44, Integrins) and increased Wnt signaling, contributing to ECM remodeling and tumor support.
Cell-cell interaction (CCI) analysis reveals a dramatic shift from normal tissue homeostasis to a pro-tumorigenic and immunosuppressive communication network. While diploid epithelial cells interact with immune cells in normal tissue (e.g., Mac-Diploid Intestinal Epi via CD86-CD28), aneuploid tumor epithelial cells become central to a new repertoire of interactions in the tumor. Prominent tumor-specific CCIs involve extensive extracellular matrix (ECM) remodeling (e.g., collagen-integrin, SPP1-integrin), angiogenesis (VEGFA-FLT1, PDGF, Notch), and immune evasion. Crucially, the tumor TME exhibits highly active immune checkpoint signaling, including PD-L2/PD-1 and CD80/CTLA4 interactions between macrophages and T cells, and significantly upregulated TGFB1-TGFbeta_receptor1 signaling. This intricate interplay underscores how tumor cells and their associated stroma actively co-opt immune cells to establish an immunosuppressive barrier. The absence of specific malignant epithelial cell interactions within the top 80 CellPhoneDB results (Image 13) may reflect that while they are active, their ligand-receptor events are perhaps more diffuse or less frequently highly ranked than the strong immune-immune and immune-stromal interactions under the selected statistical parameters.
Genetic alterations extend beyond global aneuploidy, with recurrent genomic amplifications identified on chromosomes 7 (including *EGFR*), 8q (including *MYC*), 17 (*ERBB2*), and 20q13. These amplifications are well-established oncogenic drivers in CRC and provide clear rationale for targeted therapies. Furthermore, tumor-derived Intestinal Epithelial cells exhibit a widespread and significant upregulation of a broad spectrum of cell cycle genes, directly reflecting their uncontrolled proliferation and metabolic reprogramming (e.g., oxidative phosphorylation, Wnt, Hedgehog signaling). These comprehensive findings provide robust evidence for the molecular and cellular drivers of colorectal cancer progression and offer a rich landscape for therapeutic intervention.
Hypotheses:
- The presence of aneuploid Intestinal Epithelial cells in histologically 'adjacent normal' tissue indicates a subclinical field cancerization effect, predisposing these areas to future malignant transformation.
- The observed increase in regulatory T cells (Tregs) and ILCregs, coupled with activated TGF-beta signaling from macrophages, establishes a robust immunosuppressive microenvironment that impedes effective anti-tumor immune responses in colorectal cancer.
- Tumor-associated fibroblasts (CAFs) actively contribute to an immunosuppressive and pro-metastatic niche through upregulated integrin-ECM interactions and Wnt signaling, driving tumor growth and resistance to therapy.
- The distinct surfaceome profiles of tumor-origin Intestinal Epithelial cells, tumor-associated macrophages, and CAFs, including molecules like CD47, CEACAM1, and specific integrins, facilitate immune evasion and provide novel avenues for targeted therapeutics.
- The widespread upregulation of cell cycle genes in tumor Intestinal Epithelial cells, along with specific recurrent genomic amplifications (e.g., EGFR, ERBB2, MYC), suggests a high dependency on these proliferative pathways, making them vulnerable to targeted cell cycle inhibitors.
Potential therapeutic targets:
- CD47-SIRPα axis: CD47 is highly expressed on tumor-origin Intestinal Epithelial cells and SIRPα on tumor-associated macrophages (TAMs). This interaction delivers a 'don't eat me' signal, allowing tumor cells to evade macrophage phagocytosis. Evidence: CD47 is a prominent surface marker in tumor Intestinal Epithelial cells (Section 16). SIRPα is a highly expressed surface marker in tumor macrophages (Section 17). Targeting this axis can unleash macrophage phagocytic activity (Section 17 References, PubMed Search: SIRPA CD47 cancer immunotherapy). Validation: In vitro phagocytosis assays using patient-derived macrophages and tumor cells, followed by in vivo efficacy studies with anti-CD47 or anti-SIRPα antibodies in xenograft models.
- TGFB1-TGFbeta_receptor1 pathway: TGF-beta signaling is significantly upregulated, particularly from macrophages to T cells and epithelial cells, and is a potent immunosuppressive and pro-tumorigenic pathway in the TME. Evidence: Strong upregulation of TGFB1-TGFbeta_receptor1 interactions in tumor CCIs (Section 14, 15). TGF-beta promotes T cell inhibition, Treg development, and M2-like macrophage phenotype, supporting tumor growth and metastasis (Section 14 Biological Interpretation). Validation: Evaluate the effect of TGF-beta inhibitors on T cell proliferation and cytokine production in co-culture with tumor macrophages, and assess tumor growth and immune infiltration in mouse models treated with TGF-beta blocking agents.
- EGFR (Epidermal Growth Factor Receptor): EGFR is frequently amplified in tumor-origin Intestinal Epithelial cells, driving cell proliferation and survival. Evidence: Significant amplification of the 7p12.3:7q21.12 region, containing the *EGFR* gene, is observed in tumor-origin cells across multiple samples (Section 4). EREG, an EGFR ligand, is also highly expressed in tumor Intestinal Epithelial cells (Section 16). Validation: Test response to anti-EGFR therapies (e.g., cetuximab, panitumumab) in tumor cell lines or patient-derived organoids with EGFR amplification. Correlate EGFR amplification status with clinical response in a validation cohort.
- CDK4/6 (Cyclin-Dependent Kinases 4 and 6): Core cell cycle regulators (CDK1, CDK4, CDK6) are significantly upregulated in tumor Intestinal Epithelial cells, indicating hyperactive proliferation. Evidence: Numerous cell cycle genes, including CDK4 and CDK6, show robust and widespread upregulation in Intestinal Epithelial cells from tumor samples compared to adjacent normal tissue (Section 20). Validation: Assess the anti-proliferative effects of CDK4/6 inhibitors on primary colorectal cancer cells or cell lines. Combine CDK4/6 inhibitors with other standard-of-care agents to evaluate synergistic effects in vitro and in vivo.
- Integrins (e.g., ITGAV, ITGA1, ITGA5): Various integrin subunits are highly expressed in cancer-associated fibroblasts (CAFs) and are involved in extensive ECM remodeling and tumor invasion, and in epithelial cells (ITGA2) contributing to cancer progression. Evidence: High expression of ITGA2 in tumor Intestinal Epithelial cells (Section 16). Strong upregulation of ITGAV, ITGA1, ITGA5 in tumor fibroblasts (CAFs) (Section 18). Collagen/Laminin-Integrin interactions are prominent in tumor CCIs (Section 15). Validation: Evaluate the impact of integrin-blocking antibodies or small molecule inhibitors on CAF-mediated ECM remodeling, tumor cell migration, and invasion using 3D cell culture models and in vivo metastasis assays.
Follow-up validation ideas:
- Validate the presence of aneuploid Intestinal Epithelial cells in adjacent normal tissue using FISH or targeted single-cell genomic sequencing on new patient cohorts to confirm field cancerization.
- Perform functional assays (e.g., co-culture experiments, organoids) to assess the impact of increased Tregs/ILCregs and TGF-beta signaling on CD8+ T cell cytotoxicity against primary colorectal cancer cells.
- Utilize spatial transcriptomics or multiplexed immunostaining to map the precise localization and interaction of specific CAF subsets (identified by CD44, ITGAV, PMEPA1) with tumor cells and immune cells, and evaluate their correlation with tumor invasion fronts.
- Conduct in vitro and in vivo studies (e.g., patient-derived xenografts) to test the efficacy of blocking newly identified surface markers (e.g., CEACAM1, ADGRE5, CD47 on epithelial cells; SIRPA, GPNMB on macrophages; ITGAV on fibroblasts) using antibodies or CAR T cells.
- Investigate the sensitivity of colorectal cancer cell lines and primary tumor cells with EGFR, ERBB2, or MYC amplifications to specific cell cycle inhibitors (e.g., CDK4/6 inhibitors, CHEK1 inhibitors) or pathway inhibitors (e.g., Wnt inhibitors).
Limitations:
This report is based on single-cell RNA sequencing data, which provides transcriptomic insights but does not directly measure protein expression or post-translational modifications. Cell-cell interaction inferences (CellPhoneDB) are computational predictions based on ligand and receptor expression, requiring functional validation. The identification of aneuploid cells relies on genomic inference from RNA-seq and should be orthogonally confirmed with DNA-based methods like FISH or WGS. The 'adjacent normal' samples, while histologically normal, may still harbor subtle molecular alterations or microscopic tumor cell contamination, as indicated by the presence of aneuploid cells in some cases. The patient cohort size and specific tumor stages or treatment histories were not fully detailed, which could influence the generalizability of findings. Furthermore, while numerous associations and dysregulated pathways were identified, direct causality cannot be established without further experimental perturbation studies.
24. Query List
- Show UMAP including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save it.
- Show major cell type scores on UMAP and save it.
- Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
- Select tumor-origin cells and unassigned cells, group by sample, show CNV heatmap, and include a summary of significantly amplified regions and save it.
- Show CNV patterns on UMAP. Include major cell types, minor cell types, ploidy results, conditions, and samples in 2 columns and save it.
- Show population bar plot for minor cell types and save it.
- Show subset population barplot for T cells and save it.
- Show boxplot for T cell subset populations if there are significant differences between conditions, and save it. Set ncols appropriately based on the total number of panels.
- Show subset population barplot for Macrophages and save it.
- Show boxplot for Macrophage subset populations if there are significant differences between conditions, and save it. Set ncols appropriately based on the total number of panels.
- Select tumor-origin cells and unassigned cells, and show a barplot of their ploidy population and save it.
- Show cell-cell interaction patterns by condition, including Intestinal Epithelial cells (tumor origin), Fibroblasts, Macrophages, and T cells, and save it. Limit cell-cell interactions to a maximum of 80 per condition.
- Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
- Select genes related to immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save it.
- Find statistically significant differences in cell-cell interactions between conditions for major immune and stromal cells, show as a dot plot, and save it. Set max_n_items_per_group = 25.
- Show the condition-specific markers for tumor-origin cells (Intestinal Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
- Extract condition-specific markers for Macrophages, show as a dot plot, and save it. Show only surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for Fibroblasts, show as a dot plot, and save it. Show only surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for CD4 T cells, show as a dot plot, and save it. Show only surfaceome markers, up to 50 per condition.
- Select genes related to the Cell cycle pathway, find those with statistically significant expression differences between conditions in Intestinal Epithelial cells, show as a boxplot, and save it. Set max_n_items_to_plot = 24, and set ncols appropriately to achieve a 2x3 aspect ratio based on the total number of panels.
- Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
- Show Gene set enrichment analysis results for major cell types as a dot plot and save it. Set color map to RdBu_r and n_pws_to_show = 80.





















